WO2007146417A2 - Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity - Google Patents
Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity Download PDFInfo
- Publication number
- WO2007146417A2 WO2007146417A2 PCT/US2007/014056 US2007014056W WO2007146417A2 WO 2007146417 A2 WO2007146417 A2 WO 2007146417A2 US 2007014056 W US2007014056 W US 2007014056W WO 2007146417 A2 WO2007146417 A2 WO 2007146417A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucan
- neutrophils
- cells
- tumor
- ic3b
- Prior art date
Links
- 210000000440 neutrophil Anatomy 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 231100000135 cytotoxicity Toxicity 0.000 title claims abstract description 28
- 230000003013 cytotoxicity Effects 0.000 title claims abstract description 27
- 230000001419 dependent effect Effects 0.000 title claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 8
- 230000001404 mediated effect Effects 0.000 title claims description 12
- 229920001503 Glucan Polymers 0.000 title description 61
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 178
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 174
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000002147 killing effect Effects 0.000 abstract description 9
- 230000037452 priming Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 33
- -1 β-glucan polysaccharides Chemical class 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 22
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 22
- 210000002540 macrophage Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 108010078015 Complement C3b Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 238000000605 extraction Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 11
- 230000009977 dual effect Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 210000005253 yeast cell Anatomy 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000000551 Syk Kinase Human genes 0.000 description 8
- 108010016672 Syk Kinase Proteins 0.000 description 8
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 229960004641 rituximab Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 150000002402 hexoses Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229940071127 thioglycolate Drugs 0.000 description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 6
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 5
- 108010093965 Polymyxin B Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229920000249 biocompatible polymer Polymers 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 229920000024 polymyxin B Polymers 0.000 description 5
- 229960005266 polymyxin b Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 102000006834 complement receptors Human genes 0.000 description 4
- 108010047295 complement receptors Proteins 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000002476 tumorcidal effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000005889 cellular cytotoxicity Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 108010017838 cyclo-(lysyl-prolyl-glycyl-prolyl-glycyl-glutamyl-prolyl-glycyl-prolyl-glycyl)cyclo(1epsilon-6gamma)glycyl-glycine Proteins 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 108090001082 glucan-binding proteins Proteins 0.000 description 2
- 125000005640 glucopyranosyl group Chemical group 0.000 description 2
- 239000000383 hazardous chemical Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000117 poly(dioxanone) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100365877 Caenorhabditis elegans cdl-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- NFXPEBHDHBEHQC-YZJMRIMCSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NFXPEBHDHBEHQC-YZJMRIMCSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 241001233061 earthworms Species 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003132 food thickener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 1
- 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 150000003915 phosphatidylinositol 4,5-bisphosphates Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003133 propidium iodide exclusion Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention was supported, in whole or in part, by a grant NIH ROl CA86412 from the National Institutes of Health and DAMD 17-02-01-0445 from the US Army Breast Cancer Research Program. The Government has certain rights in the invention.
- ⁇ -glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of ⁇ -glucan has a unique structure in which glucose is linked together in different ways, resulting in different physical and chemical properties. For example, ⁇ (1-3) glucan derived from bacteria and algae is linear, making it useful as a food thickener.
- ⁇ -glucan derived from yeast is branched with ⁇ (l-3) and ⁇ (l- 6) linkages with 1,3 linked glucose on the side chains, enhancing its ability to bind to and stimulate macrophages (also referred as 1,3; 1,6 glucan).
- ⁇ -glucan purified from baker's yeast is a potent anti-infective ⁇ -glucan immunomodulator.
- the cell wall of S. cerevisiae is mainly composed of ⁇ -glucans, which are responsible for its shape and mechanical strength.
- yeast While best known for its use as a food grade organism, yeast is also used as a source of zymosan, a crude insoluble extract used to stimulate a non-specific immune response.
- Yeast-derived ⁇ (1,3; 1,6) glucans stimulate the immune system, in part, by activating the innate anti-fungal immune mechanisms to fight a variety of targets.
- Glucans are structurally and functionally different depending on the source and isolation methods. ⁇ -glucans possess a diverse range of activities. The ability of ⁇ -glucan to increase nonspecific immunity and resistance to infection is similar to that of endotoxin. Early studies on the effects of ⁇ glucan on the immune system focused on mice.
- ⁇ -glucan has strong immunostimulating activity in a wide variety of other species, including earthworms, shrimp, fish, chicken, rats, rabbits, guinea pigs, sheep, pigs, cattle and humans. Based on these studies, ⁇ -glucan represents a type of immunostimulant that is active across the evolutionary spectrum, likely representing an evolutionarily innate immune response directed against fungal pathogens. However, despite extensive investigation, no consensus has been achieved on the source, size, and form of ⁇ -glucan that is actually used in at least some of the immunostimulatory functions.
- ⁇ -glucan a polysaccharide produced by barley and fungi including yeast, in combination with monoclonal antibodies hold promise for cancer therapy, ⁇ -glucans are bound by complement receptor 3 (CR3) and, in concert with target-associated complement fragment iC3b, elicit phagocytosis and killing of yeast, ⁇ -glucans may also promote killing of mammalian tumor cells bearing iC3b (which would be engendered by administration of anti-tumor mAbs). Described herein are methods of administration of ⁇ -glucan compositions to tumor bearing mice in combination with an anti-tumor mAb. This composition almost completely stops tumor growth.
- This activity derives from a 25 kD fragment of ⁇ -glucan released by macrophage processing of the parent polysaccharide. Unlike the parent ⁇ -glucan, which does not bind neutrophil CR3, the 25 kD ⁇ -glucan binds to neutrophil CR3, induces CBRM 1/5 neoepitope expression, and elicits CR3-dependent cytotoxicity. These events require phosphorylation of the tyrosine kinase, Syk, and consequent phosphatidylinositol 3-kinase (PI 3-kinase) activation, because ⁇ -glucan-mediated CR3 -dependent cytotoxicity is drastically decreased by inhibition of these signaling molecules.
- PI 3-kinase phosphatidylinositol 3-kinase
- ⁇ -glucan enhances tumor killing through a cascade of events including in vivo macrophage cleavage of the polysaccharide, dual CR3 ligation and CR3-Syk-PI3-kinase signaling.
- FIGs. 1 A-IB graphically depict the tumoricidal activity of immunotherapy with ⁇ -glucan PGG in combination with anti-tumor mAbs.
- FIG. IA is a graph of tumor diameter versus number of days post tumor implantation.
- FIG. IB is a graph of percent survival versus number of days post rumor implantation.
- FIGs. 2A-2F are a series of photographs and graphs showing macrophages accumulate soluble yeast ⁇ -glucan and process it to prime neutrophil complement receptor 3 (CR3).
- FIG. 2A is a series of photographs showing cells from spleen or bone marrow that were stained with F4/80-PE or anti-Gr-1-PE.
- FIG. 2B is a series of graphs showing percent cells with surface bound fluorescent ⁇ -glucan on particular days. The upper graph represents cells taken from the spleen, and the lower graph represents cells taken from the bone marrow.
- FIG. 2C is a series of photographs taken by confocal microscopy and also a series of graphs that represent the analysis of those cells by flow cytometry.
- FIG. 2D is a series of photographs that show peritoneal neutrophils stained with anti-Gr-1-PE.
- FIG. 2E is a graph showing the percentage of fluorescent positive neutrophils depicted in 2D.
- FIG. 2F is a graph showing the percentage of cytoxicity of the positive neutrophils depicted in 2D.
- FIGs. 3A-3F are a series of photographs and graphs showing an excreted 25 kD ⁇ -glucan binds to neutrophil CR3, priming CBRMl/5 neoepitope induction and cytotoxicity.
- FIG. 3A is a series of graphs showing peritoneal neutrophils from wildtype (WT) and CR3 V' mice that were stained with DTAF-labeled ⁇ -glucan PGG (upper panel) or with DTAF-labeled 25 kD active moiety released from macrophage culture (lower panel).
- WT wildtype
- CR3 V' mice were stained with DTAF-labeled ⁇ -glucan PGG (upper panel) or with DTAF-labeled 25 kD active moiety released from macrophage culture (lower panel).
- FIG. 3B is a series of photographs showing human CR3 transfected CHO cells stained with anti-CR3-PE (red) and DTAF-labeled parent ⁇ - glucan PGG or 25 kD ⁇ -glucan (green).
- FIG. 3C is a graph showing the percent of Gr- I + cells with bound hexose-DTAF versus concentrations of hexose.
- FIG. 3D is a graph showing percentage of neutrophils with bound hexose-DTAF versus concentrations of Hexose.
- FIG. 3E is a graph showing the percentage of human neutrophils with induced CBRM 1/5 neo-epitope versus concentrations of hexose.
- FIG. 3F is a graph showing the percentage of toxicity versus concentrations of hexose.
- FIGs. 4A-4E are a series of graphs and a photograph showing that CR3 dual ligation leads to enhanced Syk phosphorylation, augmented PI 3-kinase activity and cytotoxicity.
- FIG. 4A shows proteins that were transferred onto nitrocellulose membranes and blotted with anti-Syk antibody or anti-phospho-Syk antibody.
- FIG. 4B is a series of graphs showing peripheral blood neutrophils that were stimulated with 25 kD ⁇ -glucan only, antibody only, or both and then assessed by flow cytometry.
- FIG. 4C is a graph showing the level of PI3P3 in cells stimulated with glucan only, antibody only, or both.
- FIG. 4D is a graph showing the percentage of PI3P3 level in cells that were dual ligated in the presence or absence of PI 3-kinase inhibitor or Syk inhibitor.
- FIG. 4E is a graph showing the percentage of CR3-DCC in cells that were dual ligated in the presence or absence of PI 3-kinase inhibitor or Syk inhibitor.
- a description of preferred embodiments of the invention follows.
- a 25 kD ⁇ -glucan composition is described herein that effects the CR3- dependent priming of neutrophils and can promote neutrophil killing of iC3b-opsonized targets.
- the 25 kD glucan and not the parent glucan enhances the cytotoxicity of neutrophils against iC3b-opsonized tumor cells.
- Also described herein are methods of enhancing neutrophil cytotoxicity locally at the site of the tumor.
- the glucan is used in combination with complement activating anti -tumor monoclonal antibodies, for example, rituximab and trastuzumab.
- ⁇ -glucan a well-known biological response modifier (BRM)
- BRM biological response modifier
- hematopoiesis blood cell formation
- GM-CSF granulocyte monocyte- colony stimulating factor
- Antitumor monoclonal antibodies bind to tumors and tumor cells and activate complement, coating tumors with iC3B.
- Intraveneously administered yeast ⁇ 1,3; 1,6- glucan functions as an adjuvant for antitumor mAb by priming the inactivated C3b(iC3bZ) receptors (CR3; CDllb/CD18) of circulating granulocytes, enabling CR3 to trigger cytotoxicity of iC3b coated tumors.
- C3b(iC3bZ) receptors CR3; CDllb/CD18
- a requirement for iC3b on tumors and Cr3 on granulocytes was confirmed in C3- or CR3-
- Parent ⁇ -glucan is a soluble yeast ⁇ -glucan comprised of a ⁇ -D-(l-3)-linked glucopyranosyl backbone with ⁇ -D-(l-6)-linked ⁇ (l,3) side chains.
- the length of the side chains is between about 2 and 5 glucose residues in length.
- Suitable examples of soluble forms of parent ⁇ -glucan are described in U.S. Patent Nos.
- compositions described herein comprise a 25 kD ⁇ -glucan comprised of a ⁇ - D-(l-3)-linked glucopyranosyl backbone with ⁇ -D-(l-6)-li n l ce d ⁇ (l,3) side chains.
- the 25 kD ⁇ -glucan is a modified cleavage or degradation product produced by macrophage processing of parent ⁇ -glucan or by alternative in vitro processes utilizing various forms of starting ⁇ -glucan materials.
- the molecular weight of the 25 kD ⁇ - glucan is approximate and based on comparison to dextran standards eluted from HPLC. Depending on the method and standard used to determine molecular weight, the molecular weight of the ⁇ -glucan fragment may vary. Glucan receptor binding with CR3
- the iC3 ⁇ -receptor CR3 (also known as Mac-1, CDl lb/CD18, or ⁇ M ⁇ 2-integrin) was shown to have a ⁇ -glucan-binding lectin site that functioned in the phagocytosis of yeast cell walls by neutrophils, monocytes, and macrophages (Ross, G. D., et al, Complement Inflamm. 4:61-74 (1987) and Xia, Y., V. et al., J. Immunol. 162:2281- 2290 (1999)).
- Mac-1/CR3 functions as both an adhesion molecule mediating the diapedesis of leukocytes across the endothelium and a receptor for the iC3b fragment of complement responsible for phagocytic/degranulation responses to microorganisms.
- Mac-1/CR3 has many functional characteristics shared with other integrins, including bidirectional signaling via conformational changes that originate in either the cytoplasmic domain or extracellular region.
- GPI glycosylphosphatidylinositol
- soluble ⁇ -glucan polysaccharides that bind to its lectin site prime the Mac- 1/CR3 of circulating phagocytes and natural killer (NK) cells, permitting cytotoxic degranulation in response to iC3b-opsonized tumor cells that otherwise escape from this mechanism of cell-mediated cytotoxicity.
- NK natural killer
- CR3 binds soluble fungal ⁇ -glucan with high affinity (5 x 10 "8 M) and this primes the receptor of phagocytes or NK cells for cytotoxic degranulation in response to iC3b-coated tumor cells.
- CR3 plays a very important role in the antitumor activity of ⁇ -glucan.
- the role of CR3 in mediating the response to glucan was shown by research into the mechanisms of neutrophil phagocytosis of iC3b-opsonized yeast.
- complement C3b When complement C3b has attached itself to a surface, it may be clipped by a serum protein to produce a smaller fragment, iC3b. While iC3b has been "inactivated” and cannot function to form a membrane attack complex, it remains attached to the surface where it serves to attract neutrophils and macrophages which can phagocytize or otherwise destroy the marked ("opsonized") cell.
- CR3 complement receptors
- Stimulation of CR3 -dependent phagocytosis or degranulation requires the simultaneous ligation of two distinct sites within CR3; one specific for iC3b and a second site specific for glucan.
- Parent glucan that is transformed to the size of 25 kD and brought to the tumor site binds to the lectin site of CR3 to activate immune cells bearing the receptor to trigger degranulation and or phagocytosis of the foreign material.
- glucan described herein can be made by various methods known to one skilled in the art.
- NSG neutral soluble glucan
- this method involves treating whole glucan particles with a series of acid and alkaline treatments to produce soluble glucan that forms a clear solution at a neutral pH.
- the whole glucan particles utilized in this present invention can be in the form of a dried powder, prepared by the process described above. For the purpose of this present invention it is not necessary to conduct the final organic extraction and wash steps.
- whole glucan particles are suspended in an acid solution under conditions sufficient to dissolve the acid-soluble glucan portion.
- an acid solution having a pH of from about 1 to about 5 and a temperature of from about 20° to about 100° C. is sufficient.
- the acid used is an organic acid capable of dissolving the acid-soluble glucan portion.
- Acetic acid, at concentrations of from about 0.1 to about 5M or formic acid at concentrations of from about 50% to 98% (w/v) are useful for this purpose.
- sulphuric acid can be utilized.
- the treatment is usually carried out at about 90° C.
- the treatment time may vary from about
- modified glucans having more ⁇ (l-6) branching than naturally-occurring, or wild-type glucans require more stringent conditions, i.e., longer exposure times and higher temperatures.
- This acid-treatment step can be repeated under similar or variable conditions.
- modified whole glucan particles from the strain, 5". cerevisiae R4, which have a higher level of ⁇ (l -6) branching than naturally-occuring glucans are used, and treatment is carried out twice: first with 0.5M acetic acid at 90° C. for 3 hours and second with 0.5M acetic acid at 90° C. for 20 hours.
- the acid-insoluble glucan particles are then separated from the solution by an appropriate separation technique, for example, by centrifugation or filtration.
- the pH of the resulting slurry is adjusted with an alkaline compound such as sodium hydroxide, to a pH of about 7 to about 14.
- the slurry is then resuspended in hot alkali having a concentration and temperature sufficient to solubilize the glucan polymers.
- Alkaline compounds which can be used in this step include alkali-metal or alkali-earth metal hydroxides, such as sodium hydroxide or potassium hydroxide, having a concentration of from about 0.1 to about ION.
- This step can be conducted at a temperature of from about 4° C. to about 121° C, typically from about 20° C. to about 100° C.
- the conditions utilized are a IN solution of sodium hydroxide at a temperature of about 80°- 100° C. and a contact time of approximately 1-
- the resulting mixture contains solubilized glucan molecules and particulate glucan residue and generally has a dark brown color due to oxidation of contaminating proteins and sugars.
- the particulate residue is removed from the mixture by an appropriate separation technique, e.g., centrifugation and/or filtration.
- the resulting solution contains soluble glucan molecules.
- This solution can, optionally, be concentrated to effect a 5 to 10 fold concentration of the retentate soluble glucan fraction to obtain a soluble glucan concentration in the range of about 1 to 5 mg/ml.
- This step can be carried out by an appropriate concentration technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight levels.
- the concentrated fraction obtained after this step is enriched in the soluble, biologically active glucan, also referred to as ⁇ -glucan PGG.
- the glucan concentrate is further purified, for example, by diafiltration. In one embodiment, diafiltration is carried out using approximately 10 volumes of alkali in the range of about 0.2 to 0.4N.
- a suitable concentration of the soluble glucan after this step is from about 2 to about 5 mg/ml.
- the pH of the solution is adjusted in the range of about 7-9 with an acid, such as hydrochloric acid.
- Traces of proteinaceous material which may be present can be removed by contacting the resulting solution with a positively charged medium such as DEAE-cellulose, QAE-cellulose or Q-Sepharose. Proteinaceous material is detrimental to the quality of the glucan product, may produce a discoloration of the solution and aids in the formation of gel networks, thus limiting the solubility of the neutral glucan polymers.
- a clear solution is obtained after this step.
- the highly purified, clear glucan solution can be further purified, for example, by diafiltration, using a pharmaceutically acceptable medium (e.g., sterile water for injection, phosphate-buffered saline (PBS), isotonic saline, dextrose) suitable for parenteral administration.
- a pharmaceutically acceptable medium e.g., sterile water for injection, phosphate-buffered saline (PBS), isotonic saline, dextrose
- PBS phosphate-buffered saline
- dextrose dextrose
- the final concentration of the glucan solution is adjusted in the range of about 0.5 to 5 mg/ml.
- the solution can be terminally sterilized by filtration through a 0.22 ⁇ m filter.
- the soluble glucan preparation obtained by this process is sterile, non-antigenic, and essentially pyrogen-free, and can be stored at room temperature for extended periods of time without degradation.
- a yeast culture is grown, typically, in a shake flask or fermenter.
- a culture of yeast is started and expanded stepwise through a shake flask culture into a 250-L scale production fermenter.
- the yeast are grown in a glucose- ammonium sulfate medium enriched with vitamins, such as folic acid, inositol, nicotinic acid, pantothenic acid (calcium and sodium salt), pyridoxine HCl and thymine HCl and trace metals from compounds such as ferric chloride, hexahydrate; zinc chloride; calcium chloride, dihydrate; molybdic acid; cupric sulfate, pentahydrate and boric acid.
- vitamins such as folic acid, inositol, nicotinic acid, pantothenic acid (calcium and sodium salt), pyridoxine HCl and thymine HCl and trace metals from compounds such as ferric chloride, hexahydrate; zinc chloride; calcium chloride, dihydrate; molybdic acid; cupric sulfate, pentahydrate and boric acid.
- An S antifoaming agent such as Antifoam 204 may also be added
- the production culture is maintained under glucose limitation in a fed batch mode.
- samples are taken periodically to measure the optical density of the culture before inoculating the production fermenter.
- 0 samples are also taken periodically to measure the optical density of the culture.
- samples are taken to measure the optical density, the dry weight, and the microbial purity.
- fermentation may be terminated by raising the pH of the culture to at least 11.5 or by centrifuging the culture to separate the cells from the growth medium.
- steps to disrupt or fragment the yeast cells may be carried out. Any known chemical, enzymatic or mechanical methods, or any combination thereof may be used to carry out disruption or fragmentation of the yeast cells.
- yeast cells containing the ⁇ -glucan are harvested.
- yeast cells are typically harvested using continuous-flow centrifugation.
- Yeast cells are extracted utilizing one or more of an alkaline solution, a surfactant, or a combination thereof.
- a suitable alkaline solution is, for example, 0.1 M-5 M NaOH.
- Suitable surfactants include, for example, octylthioglucoside, Lubrol PX, Triton X-100, sodium lauryl sulfate (SDS), Nonidet P-40, Tween 20 and the like.
- Ionic (anionic, 5 cation ic, amphoteric) surfactants e.g., alkyl sulfonates, benzalkonium chlorides, and the like
- nonionic surfactants e.g., polyoxyethylene hydrogenated castor oils, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyethylene glycol fatty acid esters, polyoxyethylene alkyl phenyl ethers, and the like
- concentration of 0 surfactant will vary and depend, in part, on which surfactant is used.
- Yeast cell material may be extracted one or more times.
- Extractions are usually carried out at temperatures between about 70 0 C and about 90 0 C. Depending on the temperature, the reagents used and their concentrations, the duration of each extraction is between about 30 minutes and about 3 hours. 5 After each extraction, the solid phase containing the ⁇ -glucan is collected using centrifugation or continuous- flow centrifugation and resuspended for the subsequent step. The solubilized contaminants are removed in the liquid phase during the centrifugations, while the ⁇ -glucan remains in the insoluble cell wall material.
- harvested yeast cells are mixed with 1.0 M NaOH and heated to 90 0 C for approximately
- the second extraction is an alkaline/surfactant extraction whereby the insoluble material is resuspended in 0.1 M NaOH and about 0.5% to 0.6% Triton X-IOO and heated to 90 0 C for approximately 120 minutes.
- the third extraction is similar to the second extraction except that the concentration of Triton X-100 is about 0.05%, and the duration is shortened to about 60 minutes.
- the insoluble material is resuspended in about 0.05% Triton-X 100 and heated to 75°C for approximately 60 minutes.
- the alkaline and/or surfactant extractions solubilize and remove some of the extraneous yeast cell materials.
- the alkaline solution hydrolyzes proteins, nucleic acids, mannans, and lipids.
- Surfactant enhances the removal of lipids, which provides an additional advantage yielding an improved ⁇ -glucan product.
- the next step in the purfication process is an acidic extraction shown, which removes glycogen.
- One or more acidic extractions are accomplished by adjusting the pH of the alkaline/surfactant extracted material to between about 5 and 9 and mixing the material in about 0.05 M to about 1.0 M acetic acid at a temperature between about
- the insoluble material remaining after centrifugation of the alkaline/surfactant extraction is resuspended in water, and the pH of the solution is adjusted to about 7 with concentrated HCl.
- the material is mixed with enough glacial acetic acid to make a 0.1 M acetic acid solution, which is heated to 90 0 C for approximately 5 hours.
- the insoluble material is washed.
- the material is mixed in purified water at about room temperature for a minimum of about 20 minutes.
- the water wash is carried out two times.
- the purified ⁇ -glucan product is then collected. Again, collection is typically carried out by centrifugation or continuous- flow centrifugation.
- the product may be in the form of whole glucan particles or any portion thereof, depending on the starting material.
- larger sized particles may be broken down into smaller particles.
- the range of product sizes includes ⁇ -glucan particles that have substantially retained in vivo morphology (whole glucan particles) down to submicron-size particles.
- particulate ⁇ -glucan is useful in many food, supplement and pharmaceutical applications.
- particulate ⁇ -glucan can be processed further to form aqueous, soluble ⁇ -glucan.
- Particuate ⁇ -glucan starting material may range in size from whole glucan particles down to submicron-sized particles.
- the particulate ⁇ -glucan undergoes an acidic treatment under pressure and elevated temperature to produce soluble ⁇ -glucan.
- Pelleted, particulate ⁇ -glucan is resuspended and mixed in a sealable reaction vessel in a buffer solution and brought to pH 3.6. Buffer reagents are added such that every liter, total
- ⁇ volume, of the final suspension mixture contains about 0.61 g sodium acetate, 5.24 ml glacial acetic acid and 430 g pelleted, particulate ⁇ -glucan.
- the vessel is purged with nitrogen to remove oxygen and increase the pressure within the reaction vessel.
- the pressure inside the vessel is brought to 35 PSI, and the suspension is heated to about 135°C for between about 4.5 and 5.5 hours. It was found that under these conditions the ⁇ -glucan will solubilize. As the temperature decreases from 135°C, the amount of solubilization also decreases.
- Hazardous chemicals that have previously been used include, for example, flammable VOCs such as ether and ethanol, very strong acids such as formic acid and sulphuric acid and caustic solutions of very high pH.
- flammable VOCs such as ether and ethanol
- very strong acids such as formic acid and sulphuric acid and caustic solutions of very high pH.
- the present process is not only safer, but, by reducing the number of different chemicals used and the number of steps involved, is more economical.
- the exact duration of heat treatment is typically determined experimentally by sampling reactor contents and performing gel permeation chromatography (GPC) analyses.
- the objective is to maximize the yield of soluble material that meets specifications for high resolution-GPC (HR-GPC) profile and impurity levels, which are discussed below.
- HR-GPC high resolution-GPC
- the mixture is cooled to stop the reaction.
- the crude, solubiliz ⁇ d ⁇ -glucan may be washed and utilized in some applications at this point, however, for pharmaceutical applications further purification is performed. Any combination of one or more of the following steps may be used to purify the soluble ⁇ -glucan. Other means known in the art may also be used if desired.
- the soluble ⁇ -glucan is clarified. Suitable clarification means include, for example, centrifugation or continuous-flow centrifugation.
- the soluble ⁇ -glucan may be filtered.
- the material is filtered, for example, through a depth filter followed by a 0.2 ⁇ m filter.
- the soluble ⁇ -glucan may be conditioned at some point during previous steps in preparation for chromatography. For example, if a chromatographic step includes hydrophobic interaction chromatography (HIC), the soluble ⁇ -glucan can be conditioned to the appropriate conductivity and pH with a solution of ammonium sulphate and sodium acetate. A suitable solution is 3.0 M ammonium sulfate, 0.1 M sodium acetate, which is used to adjust the pH to 5.5.
- HIC hydrophobic interaction chromatography
- a column is packed with Tosah Toyopearl Butyl 650M resin (or equivalent). The column is packed and qualified according to the manufacturer's recommendations.
- the column equilibration flow-through Prior to loading, the column equilibration flow-through is sampled for pH, conductivity and endotoxin analyses.
- the soluble ⁇ -glucan conditioned in the higher concentration ammonium sulphate solution, is loaded and then washed.
- the nature of the soluble ⁇ -glucan is such that a majority of the product will bind to the HIC column. Low molecular weight products as well as some high molecular weight products are washed through. Soluble ⁇ -glucan remaining on the column is eluted with a buffer such as 0.2 M ammonium sulfate, 0.1 M sodium acetate, pH 5.5. Multiple cycles may be necessary to ensure that the hexose load does not exceed the capacity of the resin. Fractions are collected and analyzed for the soluble ⁇ -glucan product.
- GPC gel permeation chromatography
- a Tosah Toyopearl HW55F resin, or equivalent is utilized and packed and qualified as recommended by the manufacturer.
- the column is equilibrated and eluted using citrate-buffered saline (0.14 M sodium chloride, 0.011 M sodium citrate, pH 6.3).
- citrate-buffered saline 0.14 M sodium chloride, 0.011 M sodium citrate, pH 6.3.
- column wash samples are taken for pH, conductivity and endotoxin analyses. Again, multiple chromatography cycles may be needed to ensure that the load does not exceed the capacity of the column.
- the eluate is collected in fractions, and various combinations of samples from the fractions are analyzed to determine the combination with the optimum profile.
- sample combinations may be analyzed by HR-GPC to yield the combination having an optimized HR-GPC profile.
- HR-GPC HR-GPC
- the amount of high molecular weight (HMW) impurity, that is soluble ⁇ -glucans over 380,000 Da, is less than or equal to 10%.
- the amount of low molecular weight (LMW) impurity, under 25,000 Da, is less than or equal to 17%.
- the selected combination of fractions is subsequently pooled.
- the soluble ⁇ -glucan is purified and ready for use. Further filtration may be performed in order to sterilize the product. If desired, the hexose concentration of the product can be adjusted to about 1.0 ⁇ 0.15 mg/ml with sterile citrate- buffered saline.
- the 25 kD ⁇ -glucan is the product of macrophage processing of a parent ⁇ - glucan.
- macrophages are maintained in a bioreactor flask in macrophage growth serum-free medium, such as SFM medium, Invitrogen, Grand Island, NY. Labeled parent ⁇ -glucan is added to the culture. After about three weeks of cell culture, the cell-free fluid from the lower chamber of the bioreactor flask containing soluble fragments of ⁇ -glucan is collected.
- the ⁇ -glucan fragments are separated by, for example, high-performance liquid chromatography (HPLC) (Waters 1525, Waters Corp., Milford, MA) utilizing a monophasic gradient and separated on a Sephacryl S-200 (GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ) column. Dextran standards of known molecular weights establish an elution molecular weight profile. Fractions containing labeled material corresponding to a molecular weight of 25 kD, as detected by an appropriate detection method, are collected. The 25 kD ⁇ -glucan may be further purified and concentrated by ultracentrifugation with, for example, a Centriprep (Millipore Corp., Bedford, MA) with a 50 kD cutoff membrane.
- HPLC high-performance liquid chromatography
- the 25 kD ⁇ -glucan prepared by macrophage processing was evaluated against similarly sized ⁇ -glucans obtained during the manufacturing process for purifying parent ⁇ -glucan (data not shown).
- the sizes of these ⁇ -glucans ranged from about 10 kD to about 30 kD.
- none of the similarly sized ⁇ -glucans tested exhibited the induction activities possessed by the 25 kD ⁇ -glucan prepared by macrophage processing. It is evident, therefore, that macrophage processing modifies the 25 kD ⁇ -glucan making a unique composition possessing characteristics that are not simply based on size.
- Complement activating antibodies are antibodies directed to the tumor or tumor antigens that are able to activate one or more members of the complement cascade. In other words, an antibody that activates complement sufficiently to deposit iC3b on the tumor cells is needed.
- the antibodies are IgG subclass I or IgG subclass II.
- the present invention discloses the use of a 25 kD ⁇ -glucan with antibodies from essentially any source, including antibodies generated naturally in response to infection, antibodies generated in response to administration of a vaccine, and monoclonal antibodies directly administered as part of a therapy including the use of ⁇ - glucan.
- any antibody having complement activating features can be used in the methods described herein to enhance ⁇ -glucan on tumorcidal activity.
- the antibody can also be a naturally occurring antibody found in the subject that is able to activate complement sufficiently to allow deposition of iC3b on the tumor cells.
- Murine antibodies can be raised against any antigen associated with neoplastic (tumor) cells using techniques known in the art. In this regard, tumor cells express increased numbers of various receptors for molecules that can augment their proliferation, many of which are the products of oncogenes. Thus, a number of monoclonal antibodies have been prepared which are directed against receptors for proteins such as transferring, IL- 2, and epidermal growth factor.
- any antibody that can selectively label antigen which is to say any antibody — could have its activity enhanced through concurrent administration with ⁇ -glucan.
- This includes antibodies of the various classes, such as IgA, IgD, IgE, and IgM, as well as antibody fragments such as Fab.
- antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds a tumor antigen.
- a molecule that specifically binds to tumor is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide.
- immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
- monoclonal antibody or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen-binding site capable of immunoreacting with a particular epitope of a target tumor.
- a monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunorcacts.
- Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, e.g., polypeptide of interest or fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide.
- ELISA enzyme linked immunosorbent assay
- the antibody molecules directed against the polypeptide can be isolated from the mammal (e.g. , from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
- antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature, 256: 495-497, the human B cell hybridoma technique (Kozbor, et al. (1983) Immunol. Today, 4: 72), the EBV- hybridoma technique (Cole, et al.
- an immortal cell line typically a myeloma
- lymphocytes typically splenocytes
- the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of interest.
- a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g. , an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide.
- Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S.
- recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
- chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.
- the present invention discloses the use of 25 kD ⁇ -glucan with antibodies from essentially any source, including antibodies generated naturally in response to infection, antibodies generated in response to administration of a vaccine, and monoclonal antibodies directly administered as part of a therapy including the use of ⁇ -glucan.
- the majority of humanized mAbs containing the human IgGl Fc-region have been shown to activate complement, such as HerceptinTM (trastuzumab), RituxanTM (rituximab), and Erbitux TM (cetuximab) (Spiridon, C. I., et al, Clin, Cancer Res., 8: 1720-1730 (2002), Idusogie, E. E., et al, J.
- glucan and antibodies work synergistically.
- ⁇ -glucans could be locally administered to act synergistically with HerceptinTM, a monoclonal antibody sold by Genentech for use in immunotherapy of breast cancer.
- HerceptinTM is a mAb that recognizes the her2 cell surface antigen which is present on 20% of breast cancer cell types.
- Clinical trials have demonstrated that HerceptinTM is saving lives, but its effectiveness could be significantly enhanced through concurrent administration of ⁇ -glucan.
- Local administration of glucan along with HerceptinTM therapy could result in a significant increase in the proportion of women responding to HerceptinTM therapy with long lasting remission of their breast cancer. Currently, only 15% of women receiving HerceptinTM therapy show long lasting remission.
- rituximab Another mAb whose activity is enhanced by whole glucan particles is rituximab, a monoclonal antibody used to treat a type of non-Hodgkin's lymphoma (NHL), a cancer of the immune system.
- RituxanTM rituximab
- B-cells white blood cells
- Rituximab is a genetically engineered version of a mouse antibody that contains both human and mouse components.
- Long-acting formulations of the 25 kD ⁇ -gl ⁇ can can be prepared by stabilizing and encapsulating the gl ⁇ can into biodegradable microparticle formulations composed of polymers, for example polymers of lactic and glycolic acid.
- "Microparticles,” as that term is used herein, includes a biocompatible polymer having the glucan incorporated therein.
- the biocompatible polymer can include, for example, poly(lactic acid) or a poly(lactic acid-co-glycolic acid) copolymer.
- the microparticles can be used to deliver the glucan to a patient in need thereof, for example, in a sustained manner. In certain embodiments, the microparticle is delivered locally.
- Polymers used in the formulation of the microparticles described herein include any polymer which is biocompatible.
- Biocompatible polymers suitable for use in the present invention include biodegradable and non-biodegradable polymers and blends and copolymers thereof, as described herein.
- a polymer is biocompatible if the polymer and any degradation products of the polymer are non-toxic to the patient and also possess no significant deleterious or untoward effects on the patient's body, such as a significant immunological reaction at an injection or implantation site.
- Biodegradable means the composition will degrade or erode in vivo to form smaller chemical species. Degradation can result, for example, by enzymatic, chemical and physical processes.
- Suitable biocompatible, biodegradable polymers include, for example, poly(lactides), poly(glycolides), poly(lactide-co- glycolides), poly(lactic acid)s, poly(glycolic acid)s, polycarbonates, polyesteramides, polyanydrides, poly(amino acids), polyorthoesters, poly(dioxanone)s, poly(alkylene alkylate)s, copolymers or polyethylene glycol and polyorthoester, biodegradable polyurethane, blends thereof, and copolymers thereof.
- Suitable biocompatible, non-biodegradable polymers include non-biodegradable polymers such as, for example, polyacrylates, polymers of ethylene-vinyl acetates and other acyl substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinylchloride, polyvinyl flouride, poly(vinyl imidazole), chlorosulphonate polyolefins, polyethylene oxide, blends thereof, and copolymers thereof
- the biocompatible polymer is at least one member selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co- glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, polycaprolactone, poly(dioxan
- Acceptable molecular weights for biocompatible polymers used in this invention can be determined by a person of ordinary skill in the art taking into consideration factors such as the desired polymer degradation rate, physical properties such as mechanical strength, and the rate of dissolution of polymer in the solvent. Typically, an acceptable range of molecular weight is of about 2,000 Daltons to about 2,000,000 Daltons. In a preferred embodiment, the polymer is a biodegradable polymer or copolymer.
- the polymer is a poly(lactide-co- glycolide) (PLG) which can have lactide:glycolide ratios of about 25:75 to about 85:15 such as about 25:75, 50:50, 75:25 and 85:15, and a molecular weight of about 5,000 Daltons to about 150,000 Daltons.
- the molecular weight of the PLG has a molecular weight of about 5,000 Daltons to about 42,000 Daltons.
- Suitable solvents e.g., polymer solvents
- suitable for production of microparticles can be determined via routine experimentation using techniques well- known to those of ordinary skill in the art.
- Suitable solvents include, but are not limited to, methylene chloride, acetone, acetic acid, ethyl acetate, methyl acetate, tetrahydrofuran, dimethylsulfoxide (DMSO), methyl ethyl ketone (MEK), acetonitrile, toluene, and chloroform.
- the solvent is selected from the group consisting of methylene chloride, chloroform, ethyl acetate, methyl acetate, acetone, acetic acid, acetonitrile, dimethylsulfoxide, methyl ethyl ketone and toluene.
- the soluble ⁇ -glucan PGG (Biothera, Eagan, MN) was labeled with fluorescein dichlorotriazine (DTAF; Molecular Probes, Eugene, OR) that covalently reacts with hydroxyl groups of polysaccharides using a modification of the procedures suggested by the manufacturer. Groups of five C57BL/6 wild type mice or CR3 -deficient mice were given
- Murine resident peritoneal macrophages were maintained in a bioreactor flask (Integra Biosciences; Chur, Switzerland) in macrophage growth serum-free medium (SFM medium, Invitrogen, Grand Island, NY).
- SFM medium macrophage growth serum-free medium
- DTAF-labeled ⁇ -glucan PGG was added to the culture.
- the cell-free fluid from the lower chamber of the bioreactor containing soluble fragments of ⁇ -glucan PGG was collected. This material was separated by high-performance liquid chromatography (HPLC) (Waters 1525, Waters Corp., Milford, MA) utilizing a monophasic gradient and separated on a Sephacryl S-200 (GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ) column.
- HPLC high-performance liquid chromatography
- DTAF- labeled dextran standards of known molecular weights established an elution molecular weight profile. Fractions containing DTAF-labeled material, as detected by A 490 on a Waters 2996 Photodiode Array Detector, indicated a dominant bimodal peak containing material of 25 kD and a small peak containing remaining parent 150 kD ⁇ -glucan PGG. 25 kD fragments were further purified and concentrated by ultracentrifugation with a Centriprep (Millipore Corp., Bedford, MA) with a 50 kD cutoff membrane. These • fractions were confirmed to contain hexose by the phenol-sulfuric acid method.
- mice Cockeysville, MD were injected intraperitoneally into mice to mobilize the marginated pool of neutrophils from the bone marrow to the peritoneal cavity.
- peritoneal-infiltrating neutrophils were collected using a transfer pipette by washing the cavity 4-5 times with 2-3 mL aliquots of ice-cold complete RPMI medium.
- Neutrophils were collected from either mice or humans as described above and resuspended in complete RPMI that had been supplemented with 10 ⁇ g/mL polymyxin B (Sigma- Aldrich, St Louis, MO) to neutralize adventitious lipopolysaccharide (LPS). Neutrophils and ⁇ -glucan were incubated at 37°C in a 5% CCh humidified incubator for 3 hours. Following the incubation, cells were washed three times.
- polymyxin B Sigma- Aldrich, St Louis, MO
- Murine neutrophils were incubated with 10 ⁇ g/mL Fc block (rat anti-mouse CD 16/32 mAb; BDPharmingen, San Diego, CA) and human neutrophils were incubated with a 1/20 dilution of heat-inactivated human serum at 0.1 mL total volume for 20 minutes at room temperature to block Fc receptors and to control false-positive staining.
- murine neutrophils were additionally stained with anti-Gr-1-PE or anti- CDl 1 ⁇ -Per CP Cy 5.5. When data were acquired by flow cytometry, the cells were gated by light scatter and propidium iodide exclusion was always utilized on a control aliquot of cells to confirm >90% cell viability.
- Neutrophils were collected from human donors and resuspended in complete RPMI that was supplemented with 10 ⁇ g/mL polymyxin B (Sigma- Aldrich, St Louis, MO) to neutralize LPS. As a positive control, an aliquot of neutrophils was not supplemented with polymyxin B and was instead activated with serial dilutions of LPS to induce the neo- epitope.
- polymyxin B Sigma- Aldrich, St Louis, MO
- neutrophils were added to the wells of 96-well plates and mixed with either the DTAF-labeled parent ⁇ -glucan PGG or the DTAF-labeled 25 kD ⁇ -glucan active moiety that had been serially diluted in complete RPMI supplemented with polymyxin B or with LPS that had been serially diluted in complete RPMI.
- Neutrophils and either ⁇ -glucan or LPS were incubated at 37°C in a 5% CO2 humidified incubator for 3 hours. Following the incubation, the contents of the wells were collected and washed as described above. Inhibition of human Fc receptors was also carried out as described above.
- the neutrophils were then stained with an optimized dilution of CBRM 1/5 mouse anti-human CDl Ib mAb that detects the activation neo-epitope of CD lib.
- the primed neutrophils were added in a final volume of 0.1 mL to the iC3b-opsonized tumor cells.
- Control wells contained iC3b-opsonized tumors and non- ⁇ -glucan-primed neutrophils to measure the contribution of ADCC to the cytotoxicity.
- Cells were incubated at 37°C in a humidified 5% CO 2 incubator for 12 hours.
- the CR3-DCC cytotoxicity of target cells was calculated by measuring the ratio of the cell indices, or the relative decrease in current impedance, among wells containing iC3b-opsonized SKOV-3 cells and ⁇ -glucan- primed neutrophils and wells containing iC3b-opsonized SKO V-3 cells and non- ⁇ -glucan- primed neutrophils.
- Syk kinase inhibitor Piceatannal Sigma- Aldrich, St. Louis, MO
- PI 3-kinase inhibitor LY294002 Calbiochem, Darmstadt, Germany
- Human neutrophils were stimulated with anti-Ml/70 mAb (1 ⁇ g/ml) followed with goat-anti-rat Ig (5 ⁇ g/ml) in the presence or absence of the 25 kD active moiety of ⁇ -glucan (10 ⁇ g/ml) at 37°C.
- To detect Syk phosphorylation cells were stimulated for 30 minutes and lysed by lysis buffer. The supematants were incubated with a cocktail of anti-CR3 mAbs (OKM-I, MN-41, MO-I 5 LM-2) and 40 ⁇ l of Protein A-agarose for two hours at 4°C.
- the agarose beads were pelleted, washed three times with lysis buffer, suspended in SDS sample buffer and boiled for five minutes. The immunoprecipitates were analyzed on SDS-PAGE gel. Proteins were transferred onto nitrocellulose membranes and blotted with anti-phospho-Syk antibody or anti-Syk antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The bound antibody was detected using enhanced chemiluminescence (Cell Signaling Technology, Beverly, MA).
- PI 3-kinase activity For measurement of PI 3-kinase activity, cells were stimulated for one hour and aliquots of cell lysates adjusted for protein concentration (500 ⁇ g of protein) were incubated for two hours at 4°C with anti-PI 3-kinase p85 antibody, and immune complexes were adsorbed onto protein A-agarose for three hours. The complexes were then washed twice with lysis buffer and three times with 10 mM Tris-HCl, pH 7.4.
- cell lysates were prepared and PI-3K was immunoprecipitated with antibody against the p85 subunit and incubated with PI(4,5)P2 (phosphatidylinositol-4,5- diphosphate).
- the reaction products were incubated with a PI(3,4,5)P3 detector protein then added to a PI(3,4,5)P3-coated microplate for competitive binding.
- a peroxidase-linked secondary detection reagent and colorimetric detection were used to detect PI(3,4,5)P3 detector protein binding to the plate.
- the colorimetric signal was inversely proportional to the amount of PI(3,4,5)P3 produced by PI-3K activity.
- mice were divided into groups of ten and therapy was initiated with 14 G2a antiGD2 mAb or BCP8 anti-MUCl mAb (200 ⁇ g intravenously (i.v.) twice weekly) with or without i.v. ⁇ -glucan PGG (1200 ⁇ g/mouse, twice a week). Therapy was continued for three weeks during which time tumor measurements by calipers were calculated as the average of perpendicular diameters twice weekly. Mice were sacrificed when tumors reached 12 mm in diameter. Survival was monitored for a period of 100 days beyond the tumor implantation.
- mice or CR3-deficient mice were implanted subcutaneously with
- This tumor suppressive effect of ⁇ -glucan with mAb was not seen in CR3-deficient (CR3 7" ) mice, suggesting that soluble ⁇ -glucan mediated tumor therapy is CR3 dependent
- mice were given fluorescein DATF-labeled PGG ⁇ -glucan intravenously and were sacrificed at day 1, day 3, and day 7.
- the spleens were frozen-sectioned and slides were stained with F4/80-PE or anti-Gr-1-PE.
- Original magnification was 6OX (FIG. 2a,b).
- Cells from the spleen or bone marrow (BM) were stained with F4/80, anti-Gr-1 mAbs and analyzed by flow cytometry.
- Thioglycolate elicited macrophages or neutrophils from wildtype (WT) or CR3-deficient (CR3 V ⁇ ) mice were incubated with DTAF-labeled PGG ⁇ glucan. Cells were observed under confocal microscopy and also analyzed by flow cytometry, respectively. Original magnification was IOOX (FIG. 2c). Peritoneal neutrophils from WT and CR3 V" mice receiving DTAF-labeled ⁇ -glucan PGG were marginated by thioglycolate injection at day 7 and stained with anti-Gr-1-PE. Original magnification was IOOX (FIG. 2d).
- Granulocytes from WT mice that had not been given ⁇ -glucan served as a control for the ability of non-glucan-exposed neutrophils to kill iC3b-coated tumor cells.
- Neutrophils from WT mice, but not CR3 ⁇ ' ⁇ mice exhibited ⁇ -glucan binding by both fluorescence microscopy (FIG. 2d) and FACS analysis (FIG. 2e).
- these WT neutrophils with surface- bound ⁇ -glucan were capable of killing iC3b-opsonized RMA-S-MUCl tumor cells.
- the requirement for CR3 was confirmed by abolished tumor killing mediated by neutrophils from CR3 V' mice (FIG. 2f).
- Peritoneal neutrophils from WT and CR3 V" mice were stained with DTAF-labeled ⁇ -glucan PGG (FIG. 3a-upper panel) or with DTAF-labeled 25 kD active moiety released from macrophage culture (FIG. 3a-lower panel).
- Human CR3 transfected CHO cells were cultured in glass-plates and stained with anti-CR3-PE and DTAF-labeled parent ⁇ -glucan PGG or 25 kD ⁇ -glucan (FIG. 3b). Slides were observed under Nikon fluorescent microscope. Original magnification was 2OX.
- Peritoneal neutrophils from WT and CR3 V" mice or human peripheral blood neutrophils were stained with various amounts of DTAF- labeled parent ⁇ -glucan PGG or 25 kD ⁇ -glucan.
- the cells with surface bound fluorescent ⁇ -glucan were gated on Gr-I + cells (FIG. 3c,d).
- Human peripheral blood neutrophils were incubated with varying concentrations of parent ⁇ -glucan PGG or 25 kD ⁇ -glucan and stained with anti-CBRMl/5 mAb (FIG. 3e).
- Human neutrophils were co-cultured with iC3b-opsonized SKO V-3 tumor cells in the presence of varying concentrations of parent ⁇ - glucan PGG or 25 kD ⁇ -glucan for cytotoxicity assay as described in the methods (FIG. 3f).
- the E:T ratio was 20: 1.
- the 25 kD ⁇ -glucan fragment could effect the CR3-dependent priming of neutrophils and might promote neutrophil killing of iC3b-opsonized targets.
- the 25 kD ⁇ -glucan, but not parent ⁇ -glucan greatly amplified the cytotoxicity of neutrophils against iC3 ⁇ -ops ⁇ nized human ovarian carcinoma cells in a dose-dependent fashion (FIG. 3f). Therefore, the 25 kD ⁇ -glucan, not the parent ⁇ -glucan, is necessary and sufficient for CR3-dependent, neutrophil-mediated cytotoxicity against iC3b-opsonized tumor cells.
- Human peripheral blood neutrophils were stimulated with rat anti-human/mouse CR3 I-domain mAb M 1/70 followed by goat anti-rat secondary antibody (with or without 25 kD ⁇ -glucan) or 25 kD ⁇ -glucan alone for 30 minutes.
- Cell lysates were immunoprecipitated with a cocktail of anti-CR3 mAbs and the immunoprecipitates were analyzed on SDS- PAGE gel. Proteins were transferred onto nitrocellulose membranes and blotted with anti- Syk antibody or anti-phospho-Syk antibody, respectively (FIG. 4a).
- Human peripheral blood neutrophils were also stimulated with 25 kD ⁇ -glucan, M 1/70 mAb followed by secondary Ab, or both for 30 minutes. Cells were fixed, permeabilized and stained with antiphospho-Syk mAb or isotype control antibody. Cells were assessed by flow cytometry. Mean fluorescence intensity was compared in each stimulation condition (FIG. 4b).
- human peripheral blood neutrophils were stimulated with Ml/70 mAb followed by secondary Ab (with or without 25 kD ⁇ -glucan) or 25 kD ⁇ -glucan alone for one hour.
- Cell lysates were immunoprecipitated with anti-PI 3-kinase p85 mAb.
- the immuprecipitates were analyzed on SDS-PAGE gel and blotted with anti-PI 3-kinase p85 mAb.
- the immunprecipitates were also measured for PI 3-kinase activity by ELISA.
- the PI 3-kinase activity was represented as the level of PI(3,4,5)P3 (PI3P3) (FIG. 4c).
- Human peripheral blood neutrophils were also stimulated with M 1/70 mAb followed by secondary Ab with 25 kD ⁇ -glucan in the presence or absence of PI 3-kinase inhibitor LY294002 (50 ⁇ M) and/or Syk kinase inhibitor Piceatannol (25 ⁇ M) for one hour.
- Cells were imtnunoprecipated with anti-PI 3-kinase p85 mAb and PI 3-kinase activity was measured by ELISA.
- the PI 3-kinase activity was arbitrarily setup as 100% for neutrophils stimulated with dual ligation (31.45 ⁇ 3.8 pM).
- the percentage of PI 3-kinase activity was generated by PI 3-kinase activity from inhibitor treated cells divided by that from dual ligation stimulated cells (9.05 ⁇ 1.14 />M for LY294002 and 17.1 ⁇ 1.5 pM. for Piceatannol, respectively) (FIG. 4d).
- human neutrophils were co-cultured with iC3b-opsonized SKOV-3 tumor cells and 25 kD ⁇ -glucan in the presence or absence of PI 3-kinase inhibitor LY294002 (50 ⁇ M) and/or Syk kinase inhibitor Piceatannol (25 ⁇ M).
- the E:T ratio was 20:1.
- the cytotoxicity was arbitrarily set up as 100% for neutrophils stimulated with 25 kD ⁇ -glucan (35.7% ⁇ 3.61%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A 25 kD β-glucan composition is described herein that effects the CR3-dependent priming of neutrophils and can promote neutrophil killing of iC3b-opsonized targets. Also described herein are methods of enhancing neutrophil cytotoxicity locally at the site of the tumor.
Description
Glucan Compositions and Methods of Enhancing CR3 Dependent Neutrophil-Mediated Cytotoxicity
GOVERNMENT SUPPORT
The invention was supported, in whole or in part, by a grant NIH ROl CA86412 from the National Institutes of Health and DAMD 17-02-01-0445 from the US Army Breast Cancer Research Program. The Government has certain rights in the invention.
BACKGROUND OF THE INVENTION
This application claims the benefit of U.S. Serial No. 60/814,148 entitled GLUCAN COMPOSITIONS AND METHODS OF ENHANCING CR3 DEPENDENT • NEUTROPHIL-MEDIATED CYTOTOXICITY, filed June 15, 2006. β-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of β-glucan has a unique structure in which glucose is linked together in different ways, resulting in different physical and chemical properties. For example, β (1-3) glucan derived from bacteria and algae is linear, making it useful as a food thickener. The frequency of side chains, known as the degree of substitution or branching frequency, regulated secondary structure and solubility, β-glucan derived from yeast is branched with β(l-3) and β(l- 6) linkages with 1,3 linked glucose on the side chains, enhancing its ability to bind to and stimulate macrophages (also referred as 1,3; 1,6 glucan). β-glucan purified from baker's yeast (Saccharomyces cerevisiae) is a potent anti-infective β-glucan immunomodulator. The cell wall of S. cerevisiae is mainly composed of β-glucans, which are responsible for its shape and mechanical strength. While best known for its use as a food grade organism, yeast is also used as a source of zymosan, a crude insoluble extract used to stimulate a non-specific immune response. Yeast-derived β (1,3; 1,6) glucans stimulate the immune system, in part, by activating the innate anti-fungal immune mechanisms to fight a variety of targets. Glucans are structurally and functionally different depending on the source and isolation methods.
β-glucans possess a diverse range of activities. The ability of β-glucan to increase nonspecific immunity and resistance to infection is similar to that of endotoxin. Early studies on the effects of β glucan on the immune system focused on mice. Subsequent studies demonstrated that β-glucan has strong immunostimulating activity in a wide variety of other species, including earthworms, shrimp, fish, chicken, rats, rabbits, guinea pigs, sheep, pigs, cattle and humans. Based on these studies, β-glucan represents a type of immunostimulant that is active across the evolutionary spectrum, likely representing an evolutionarily innate immune response directed against fungal pathogens. However, despite extensive investigation, no consensus has been achieved on the source, size, and form of β-glucan that is actually used in at least some of the immunostimulatory functions.
SUMMARY OF THE INVENTION β-glucan, a polysaccharide produced by barley and fungi including yeast, in combination with monoclonal antibodies hold promise for cancer therapy, β-glucans are bound by complement receptor 3 (CR3) and, in concert with target-associated complement fragment iC3b, elicit phagocytosis and killing of yeast, β-glucans may also promote killing of mammalian tumor cells bearing iC3b (which would be engendered by administration of anti-tumor mAbs). Described herein are methods of administration of β-glucan compositions to tumor bearing mice in combination with an anti-tumor mAb. This composition almost completely stops tumor growth. This activity derives from a 25 kD fragment of β-glucan released by macrophage processing of the parent polysaccharide. Unlike the parent β-glucan, which does not bind neutrophil CR3, the 25 kD β-glucan binds to neutrophil CR3, induces CBRM 1/5 neoepitope expression, and elicits CR3-dependent cytotoxicity. These events require phosphorylation of the tyrosine kinase, Syk, and consequent phosphatidylinositol 3-kinase (PI 3-kinase) activation, because β-glucan-mediated CR3 -dependent cytotoxicity is drastically decreased by inhibition of these signaling molecules. Thus, β-glucan enhances tumor killing through a cascade of events including in vivo macrophage cleavage of the polysaccharide, dual CR3 ligation and CR3-Syk-PI3-kinase signaling.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee FIGs. 1 A-IB graphically depict the tumoricidal activity of immunotherapy with β-glucan PGG in combination with anti-tumor mAbs. FIG. IA is a graph of tumor diameter versus number of days post tumor implantation. FIG. IB is a graph of percent survival versus number of days post rumor implantation.
FIGs. 2A-2F are a series of photographs and graphs showing macrophages accumulate soluble yeast β-glucan and process it to prime neutrophil complement receptor 3 (CR3). FIG. 2A is a series of photographs showing cells from spleen or bone marrow that were stained with F4/80-PE or anti-Gr-1-PE. FIG. 2B is a series of graphs showing percent cells with surface bound fluorescent β-glucan on particular days. The upper graph represents cells taken from the spleen, and the lower graph represents cells taken from the bone marrow. FIG. 2C is a series of photographs taken by confocal microscopy and also a series of graphs that represent the analysis of those cells by flow cytometry. FIG. 2D is a series of photographs that show peritoneal neutrophils stained with anti-Gr-1-PE. FIG. 2E is a graph showing the percentage of fluorescent positive neutrophils depicted in 2D. FIG. 2F is a graph showing the percentage of cytoxicity of the positive neutrophils depicted in 2D.
FIGs. 3A-3F are a series of photographs and graphs showing an excreted 25 kD β-glucan binds to neutrophil CR3, priming CBRMl/5 neoepitope induction and cytotoxicity. FIG. 3A is a series of graphs showing peritoneal neutrophils from wildtype (WT) and CR3V' mice that were stained with DTAF-labeled β-glucan PGG (upper panel) or with DTAF-labeled 25 kD active moiety released from macrophage culture (lower panel). FIG. 3B is a series of photographs showing human CR3 transfected CHO cells stained with anti-CR3-PE (red) and DTAF-labeled parent β- glucan PGG or 25 kD β-glucan (green). FIG. 3C is a graph showing the percent of Gr- I+ cells with bound hexose-DTAF versus concentrations of hexose. FIG. 3D is a graph showing percentage of neutrophils with bound hexose-DTAF versus concentrations of Hexose. FIG. 3E is a graph showing the percentage of human neutrophils with induced
CBRM 1/5 neo-epitope versus concentrations of hexose. FIG. 3F is a graph showing the percentage of toxicity versus concentrations of hexose.
FIGs. 4A-4E are a series of graphs and a photograph showing that CR3 dual ligation leads to enhanced Syk phosphorylation, augmented PI 3-kinase activity and cytotoxicity. FIG. 4A shows proteins that were transferred onto nitrocellulose membranes and blotted with anti-Syk antibody or anti-phospho-Syk antibody. FIG. 4B is a series of graphs showing peripheral blood neutrophils that were stimulated with 25 kD β-glucan only, antibody only, or both and then assessed by flow cytometry. FIG. 4C is a graph showing the level of PI3P3 in cells stimulated with glucan only, antibody only, or both. FIG. 4D is a graph showing the percentage of PI3P3 level in cells that were dual ligated in the presence or absence of PI 3-kinase inhibitor or Syk inhibitor. FIG. 4E is a graph showing the percentage of CR3-DCC in cells that were dual ligated in the presence or absence of PI 3-kinase inhibitor or Syk inhibitor.
DETAILED DESCRIPTION OF THE INVENTION
A description of preferred embodiments of the invention follows. A 25 kD β-glucan composition is described herein that effects the CR3- dependent priming of neutrophils and can promote neutrophil killing of iC3b-opsonized targets. As shown herein, the 25 kD glucan and not the parent glucan enhances the cytotoxicity of neutrophils against iC3b-opsonized tumor cells. Also described herein are methods of enhancing neutrophil cytotoxicity locally at the site of the tumor. In certain embodiments, the glucan is used in combination with complement activating anti -tumor monoclonal antibodies, for example, rituximab and trastuzumab. Advantages include efficient, local delivery at the tumor site, direct delivery without any prior processing, development of sustained release composition, the number of administrations may be cut down to a weekly rather than daily basis and the glucan may be effective in immunologically-impaired individuals that are unable to efficiently metabolize the parent polysaccharide. β-glucan, a well-known biological response modifier (BRM), stimulates hematopoiesis (blood cell formation) in an analogous manner as granulocyte monocyte-
colony stimulating factor (GM-CSF). Described herein are methods and compositions of 25 kD β-glucan compositions in combination with antitumor monoclonal antibodies for enhanced tumor killing.
Antitumor monoclonal antibodies bind to tumors and tumor cells and activate complement, coating tumors with iC3B. Intraveneously administered yeast β 1,3; 1,6- glucan functions as an adjuvant for antitumor mAb by priming the inactivated C3b(iC3bZ) receptors (CR3; CDllb/CD18) of circulating granulocytes, enabling CR3 to trigger cytotoxicity of iC3b coated tumors. Recent data indicated that orally administered yeast βl,3;l,6-glucan potentiated the activity of antitumor mAb, leading to enhanced tumor regression and survival. (Hong, F. et al, J. of Immunology, 173:797- 806(2004)). A requirement for iC3b on tumors and Cr3 on granulocytes was confirmed in C3- or CR3- deficient mice models.
Parent β-glucan, as described herein, is a soluble yeast β-glucan comprised of a β-D-(l-3)-linked glucopyranosyl backbone with β-D-(l-6)-linked β(l,3) side chains. The length of the side chains is between about 2 and 5 glucose residues in length. Suitable examples of soluble forms of parent β-glucan are described in U.S. Patent Nos. 7,022,685; 6,369,216; 6,117,850; 6,046,323; 5,817,643; 5,849,720; 5,811,542; 5,783,569; 5,663,324; 5,633,369; 5,622,940; 5,622,939; 5,532,223; 5,488,040 and 5,322,841, which are assigned to Biopolymer Engineering, Inc. Additional methods of preparing compositions of parent β-glucan are described below.
The compositions described herein comprise a 25 kD β-glucan comprised of a β- D-(l-3)-linked glucopyranosyl backbone with β-D-(l-6)-linlced β(l,3) side chains. The 25 kD β-glucan is a modified cleavage or degradation product produced by macrophage processing of parent β-glucan or by alternative in vitro processes utilizing various forms of starting β-glucan materials. The molecular weight of the 25 kD β- glucan is approximate and based on comparison to dextran standards eluted from HPLC. Depending on the method and standard used to determine molecular weight, the molecular weight of the β-glucan fragment may vary.
Glucan receptor binding with CR3
The iC3β-receptor CR3 (also known as Mac-1, CDl lb/CD18, or αMβ2-integrin) was shown to have a β-glucan-binding lectin site that functioned in the phagocytosis of yeast cell walls by neutrophils, monocytes, and macrophages (Ross, G. D., et al, Complement Inflamm. 4:61-74 (1987) and Xia, Y., V. et al., J. Immunol. 162:2281- 2290 (1999)). Mac-1/CR3 functions as both an adhesion molecule mediating the diapedesis of leukocytes across the endothelium and a receptor for the iC3b fragment of complement responsible for phagocytic/degranulation responses to microorganisms. Mac-1/CR3 has many functional characteristics shared with other integrins, including bidirectional signaling via conformational changes that originate in either the cytoplasmic domain or extracellular region. Another key to its functions is its ability to form membrane complexes with glycosylphosphatidylinositol (GPI)-anchored receptors such as Fc gammaRIIIB (CD 16b) or uPAR (CD87), providing a transmembrane signaling mechanism for these outer membrane bound receptors that allows them to mediate cytoskeleton-dependent adhesion or phagocytosis and degranulation. Many functions appear to depend upon a membrane-proximal lectin site responsible for recognition of either microbial surface polysaccharides or GPI-linked signaling partners. Because of the importance of Mac-1/CR3 in promoting neutrophil inflammatory responses, therapeutic strategies to antagonize its functions have shown promise in treating both autoimmune diseases and ischemia/reperfusion injury. Conversely, soluble β-glucan polysaccharides that bind to its lectin site prime the Mac- 1/CR3 of circulating phagocytes and natural killer (NK) cells, permitting cytotoxic degranulation in response to iC3b-opsonized tumor cells that otherwise escape from this mechanism of cell-mediated cytotoxicity. CR3 binds soluble fungal β-glucan with high affinity (5 x 10"8 M) and this primes the receptor of phagocytes or NK cells for cytotoxic degranulation in response to iC3b-coated tumor cells. The tumoricidal response promoted by soluble β-glucan in mice was shown to be absent in mice deficient in either serum C3 (complement 3) or leukocyte CR3, highlighting the requirement for iC3b on tumors and CR3 on leukocytes in the tumoricidal function of
β-glucans (Vetvicka, V., et al., J. Clin. Invest. 98:50-61 (1996) and Yan, J., V. et al., J. Immunol. 163:3045-3052 (1999)).
CR3 plays a very important role in the antitumor activity of β-glucan. The role of CR3 in mediating the response to glucan was shown by research into the mechanisms of neutrophil phagocytosis of iC3b-opsonized yeast. When complement C3b has attached itself to a surface, it may be clipped by a serum protein to produce a smaller fragment, iC3b. While iC3b has been "inactivated" and cannot function to form a membrane attack complex, it remains attached to the surface where it serves to attract neutrophils and macrophages which can phagocytize or otherwise destroy the marked ("opsonized") cell. On the surface of neutrophils and macrophages are complement receptors (CR3) that bind to iC3b.
Stimulation of CR3 -dependent phagocytosis or degranulation requires the simultaneous ligation of two distinct sites within CR3; one specific for iC3b and a second site specific for glucan. Parent glucan that is transformed to the size of 25 kD and brought to the tumor site binds to the lectin site of CR3 to activate immune cells bearing the receptor to trigger degranulation and or phagocytosis of the foreign material.
Preparation of parent and starting forms of β-glucan The glucan described herein can be made by various methods known to one skilled in the art. For example, the preparation of neutral soluble glucan (NSG) is' described in U.S. Pat. No. 5,322,841, the disclosure of which is incorporated herein by reference. Briefly, this method involves treating whole glucan particles with a series of acid and alkaline treatments to produce soluble glucan that forms a clear solution at a neutral pH. The whole glucan particles utilized in this present invention can be in the form of a dried powder, prepared by the process described above. For the purpose of this present invention it is not necessary to conduct the final organic extraction and wash steps.
In the present process, whole glucan particles are suspended in an acid solution under conditions sufficient to dissolve the acid-soluble glucan portion. For most
glucans, an acid solution having a pH of from about 1 to about 5 and a temperature of from about 20° to about 100° C. is sufficient. Typically, the acid used is an organic acid capable of dissolving the acid-soluble glucan portion. Acetic acid, at concentrations of from about 0.1 to about 5M or formic acid at concentrations of from about 50% to 98% (w/v) are useful for this purpose. Additionally, sulphuric acid can be utilized. The treatment is usually carried out at about 90° C. The treatment time may vary from about
1 hour to about 20 hours depending on the acid concentration, temperature and source of whole glucan particles. For example, modified glucans having more β(l-6) branching than naturally-occurring, or wild-type glucans, require more stringent conditions, i.e., longer exposure times and higher temperatures. This acid-treatment step can be repeated under similar or variable conditions. In one embodiment of the present method, modified whole glucan particles from the strain, 5". cerevisiae R4, which have a higher level of β(l -6) branching than naturally-occuring glucans, are used, and treatment is carried out twice: first with 0.5M acetic acid at 90° C. for 3 hours and second with 0.5M acetic acid at 90° C. for 20 hours.
The acid-insoluble glucan particles are then separated from the solution by an appropriate separation technique, for example, by centrifugation or filtration. The pH of the resulting slurry is adjusted with an alkaline compound such as sodium hydroxide, to a pH of about 7 to about 14. The slurry is then resuspended in hot alkali having a concentration and temperature sufficient to solubilize the glucan polymers. Alkaline compounds which can be used in this step include alkali-metal or alkali-earth metal hydroxides, such as sodium hydroxide or potassium hydroxide, having a concentration of from about 0.1 to about ION. This step can be conducted at a temperature of from about 4° C. to about 121° C, typically from about 20° C. to about 100° C. In one embodiment of the process, the conditions utilized are a IN solution of sodium hydroxide at a temperature of about 80°- 100° C. and a contact time of approximately 1-
2 hours. The resulting mixture contains solubilized glucan molecules and particulate glucan residue and generally has a dark brown color due to oxidation of contaminating proteins and sugars. The particulate residue is removed from the mixture by an appropriate separation technique, e.g., centrifugation and/or filtration.
The resulting solution contains soluble glucan molecules. This solution can, optionally, be concentrated to effect a 5 to 10 fold concentration of the retentate soluble glucan fraction to obtain a soluble glucan concentration in the range of about 1 to 5 mg/ml. This step can be carried out by an appropriate concentration technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight levels.
The concentrated fraction obtained after this step is enriched in the soluble, biologically active glucan, also referred to as β-glucan PGG. To obtain a pharmacologically acceptable solution, the glucan concentrate is further purified, for example, by diafiltration. In one embodiment, diafiltration is carried out using approximately 10 volumes of alkali in the range of about 0.2 to 0.4N. A suitable concentration of the soluble glucan after this step is from about 2 to about 5 mg/ml. The pH of the solution is adjusted in the range of about 7-9 with an acid, such as hydrochloric acid. Traces of proteinaceous material which may be present can be removed by contacting the resulting solution with a positively charged medium such as DEAE-cellulose, QAE-cellulose or Q-Sepharose. Proteinaceous material is detrimental to the quality of the glucan product, may produce a discoloration of the solution and aids in the formation of gel networks, thus limiting the solubility of the neutral glucan polymers. A clear solution is obtained after this step.
The highly purified, clear glucan solution can be further purified, for example, by diafiltration, using a pharmaceutically acceptable medium (e.g., sterile water for injection, phosphate-buffered saline (PBS), isotonic saline, dextrose) suitable for parenteral administration. The final concentration of the glucan solution is adjusted in the range of about 0.5 to 5 mg/ml. In accordance with pharmaceutical manufacturing standards for parenteral products, the solution can be terminally sterilized by filtration through a 0.22 μm filter. The soluble glucan preparation obtained by this process is sterile, non-antigenic, and essentially pyrogen-free, and can be stored at room temperature for extended periods of time without degradation.
In alternative methods for preparing particulate and soluble β-glucan, a yeast culture is grown, typically, in a shake flask or fermenter. In one embodiment of bulk production, a culture of yeast is started and expanded stepwise through a shake flask culture into a 250-L scale production fermenter. The yeast are grown in a glucose-
ammonium sulfate medium enriched with vitamins, such as folic acid, inositol, nicotinic acid, pantothenic acid (calcium and sodium salt), pyridoxine HCl and thymine HCl and trace metals from compounds such as ferric chloride, hexahydrate; zinc chloride; calcium chloride, dihydrate; molybdic acid; cupric sulfate, pentahydrate and boric acid. An S antifoaming agent such as Antifoam 204 may also be added at a concentration of about 0.02%.
The production culture is maintained under glucose limitation in a fed batch mode. During seed fermentation, samples are taken periodically to measure the optical density of the culture before inoculating the production fermenter. During production fermentation, 0 samples are also taken periodically to measure the optical density of the culture. At the end of fermentation, samples are taken to measure the optical density, the dry weight, and the microbial purity.
If desired, fermentation may be terminated by raising the pH of the culture to at least 11.5 or by centrifuging the culture to separate the cells from the growth medium. In 5 addition, depending on the size and form of purified β-glucan that is desired, steps to disrupt or fragment the yeast cells may be carried out. Any known chemical, enzymatic or mechanical methods, or any combination thereof may be used to carry out disruption or fragmentation of the yeast cells.
The yeast cells containing the β-glucan are harvested. When producing bulk β- 0 glucan, yeast cells are typically harvested using continuous-flow centrifugation.
Yeast cells are extracted utilizing one or more of an alkaline solution, a surfactant, or a combination thereof. A suitable alkaline solution is, for example, 0.1 M-5 M NaOH. Suitable surfactants include, for example, octylthioglucoside, Lubrol PX, Triton X-100, sodium lauryl sulfate (SDS), Nonidet P-40, Tween 20 and the like. Ionic (anionic, 5 cation ic, amphoteric) surfactants (e.g., alkyl sulfonates, benzalkonium chlorides, and the like) and nonionic surfactants (e.g., polyoxyethylene hydrogenated castor oils, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyethylene glycol fatty acid esters, polyoxyethylene alkyl phenyl ethers, and the like) may also be used. The concentration of 0 surfactant will vary and depend, in part, on which surfactant is used. Yeast cell material may be extracted one or more times.
Extractions are usually carried out at temperatures between about 700C and about 900C. Depending on the temperature, the reagents used and their concentrations, the duration of each extraction is between about 30 minutes and about 3 hours. 5 After each extraction, the solid phase containing the β-glucan is collected using
centrifugation or continuous- flow centrifugation and resuspended for the subsequent step. The solubilized contaminants are removed in the liquid phase during the centrifugations, while the β-glucan remains in the insoluble cell wall material.
In one embodiment, four extractions are carried out. In the first extraction, harvested yeast cells are mixed with 1.0 M NaOH and heated to 900C for approximately
60 minutes. The second extraction is an alkaline/surfactant extraction whereby the insoluble material is resuspended in 0.1 M NaOH and about 0.5% to 0.6% Triton X-IOO and heated to 900C for approximately 120 minutes. The third extraction is similar to the second extraction except that the concentration of Triton X-100 is about 0.05%, and the duration is shortened to about 60 minutes. In the fourth extraction, the insoluble material is resuspended in about 0.05% Triton-X 100 and heated to 75°C for approximately 60 minutes.
The alkaline and/or surfactant extractions solubilize and remove some of the extraneous yeast cell materials. The alkaline solution hydrolyzes proteins, nucleic acids, mannans, and lipids. Surfactant enhances the removal of lipids, which provides an additional advantage yielding an improved β-glucan product.
The next step in the purfication process is an acidic extraction shown, which removes glycogen. One or more acidic extractions are accomplished by adjusting the pH of the alkaline/surfactant extracted material to between about 5 and 9 and mixing the material in about 0.05 M to about 1.0 M acetic acid at a temperature between about
700C and 1000C for approximately 30 minutes to about 12 hours.
In one embodiment, the insoluble material remaining after centrifugation of the alkaline/surfactant extraction is resuspended in water, and the pH of the solution is adjusted to about 7 with concentrated HCl. The material is mixed with enough glacial acetic acid to make a 0.1 M acetic acid solution, which is heated to 900C for approximately 5 hours.
Next, the insoluble material is washed. In a typical wash step, the material is mixed in purified water at about room temperature for a minimum of about 20 minutes. The water wash is carried out two times. The purified β-glucan product is then collected. Again, collection is typically carried out by centrifugation or continuous- flow centrifugation.
At this point, a purified, particulate β-glucan product is formed. The product may be in the form of whole glucan particles or any portion thereof, depending on the starting
material. In addition, larger sized particles may be broken down into smaller particles. The range of product sizes includes β-glucan particles that have substantially retained in vivo morphology (whole glucan particles) down to submicron-size particles.
As is well known in the art, particulate β-glucan is useful in many food, supplement and pharmaceutical applications. Alternatively, particulate β-glucan can be processed further to form aqueous, soluble β-glucan.
Particuate β-glucan starting material may range in size from whole glucan particles down to submicron-sized particles. The particulate β-glucan undergoes an acidic treatment under pressure and elevated temperature to produce soluble β-glucan. Pelleted, particulate β-glucan is resuspended and mixed in a sealable reaction vessel in a buffer solution and brought to pH 3.6. Buffer reagents are added such that every liter, total
■ volume, of the final suspension mixture contains about 0.61 g sodium acetate, 5.24 ml glacial acetic acid and 430 g pelleted, particulate β-glucan. The vessel is purged with nitrogen to remove oxygen and increase the pressure within the reaction vessel. In a particular embodiment, the pressure inside the vessel is brought to 35 PSI, and the suspension is heated to about 135°C for between about 4.5 and 5.5 hours. It was found that under these conditions the β-glucan will solubilize. As the temperature decreases from 135°C, the amount of solubilization also decreases.
It should be noted that this temperature and pressure are required in the embodiment just described. Optimization of temperatures and pressures may be required if any of the reaction conditions and/or reagents are altered.
The increased pressure and temperature imparts advantages over prior art processes for solubilizing β-glucan by virtually eliminating the use of hazardous chemicals from the process. Hazardous chemicals that have previously been used include, for example, flammable VOCs such as ether and ethanol, very strong acids such as formic acid and sulphuric acid and caustic solutions of very high pH. The present process is not only safer, but, by reducing the number of different chemicals used and the number of steps involved, is more economical.
The exact duration of heat treatment is typically determined experimentally by sampling reactor contents and performing gel permeation chromatography (GPC) analyses. The objective is to maximize the yield of soluble material that meets specifications for high resolution-GPC (HR-GPC) profile and impurity levels, which are discussed below. Once the β-glucan is solubilized, the mixture is cooled to stop the reaction.
The crude, solubilizβd β-glucan may be washed and utilized in some applications at this point, however, for pharmaceutical applications further purification is performed. Any combination of one or more of the following steps may be used to purify the soluble β-glucan. Other means known in the art may also be used if desired. First, the soluble β-glucan is clarified. Suitable clarification means include, for example, centrifugation or continuous-flow centrifugation.
Next, the soluble β-glucan may be filtered. In one embodiment, the material is filtered, for example, through a depth filter followed by a 0.2 μm filter.
Chromatography may be used for further purification. The soluble β-glucan may be conditioned at some point during previous steps in preparation for chromatography. For example, if a chromatographic step includes hydrophobic interaction chromatography (HIC), the soluble β-glucan can be conditioned to the appropriate conductivity and pH with a solution of ammonium sulphate and sodium acetate. A suitable solution is 3.0 M ammonium sulfate, 0.1 M sodium acetate, which is used to adjust the pH to 5.5. In one example of HIC, a column is packed with Tosah Toyopearl Butyl 650M resin (or equivalent). The column is packed and qualified according to the manufacturer's recommendations.
Prior to loading, the column equilibration flow-through is sampled for pH, conductivity and endotoxin analyses. The soluble β-glucan, conditioned in the higher concentration ammonium sulphate solution, is loaded and then washed. The nature of the soluble β-glucan is such that a majority of the product will bind to the HIC column. Low molecular weight products as well as some high molecular weight products are washed through. Soluble β-glucan remaining on the column is eluted with a buffer such as 0.2 M ammonium sulfate, 0.1 M sodium acetate, pH 5.5. Multiple cycles may be necessary to ensure that the hexose load does not exceed the capacity of the resin. Fractions are collected and analyzed for the soluble β-glucan product.
Another chromatographic step that may be utilized is gel permeation chromatography (GPC). In one example of GPC, a Tosah Toyopearl HW55F resin, or equivalent is utilized and packed and qualified as recommended by the manufacturer. The column is equilibrated and eluted using citrate-buffered saline (0.14 M sodium chloride, 0.011 M sodium citrate, pH 6.3). Prior to loading, column wash samples are taken for pH, conductivity and endotoxin analyses. Again, multiple chromatography cycles may be needed to ensure that the load does not exceed the capacity of the column.
The eluate is collected in fractions, and various combinations of samples from the
fractions are analyzed to determine the combination with the optimum profile. For example, sample combinations may be analyzed by HR-GPC to yield the combination having an optimized HR-GPC profile. In one optimized profile, the amount of high molecular weight (HMW) impurity, that is soluble β-glucans over 380,000 Da, is less than or equal to 10%. The amount of low molecular weight (LMW) impurity, under 25,000 Da, is less than or equal to 17%. The selected combination of fractions is subsequently pooled.
At this point, the soluble β-glucan is purified and ready for use. Further filtration may be performed in order to sterilize the product. If desired, the hexose concentration of the product can be adjusted to about 1.0 ± 0.15 mg/ml with sterile citrate- buffered saline.
Preparation of the 25 IdD β-glucan
The 25 kD β-glucan is the product of macrophage processing of a parent β- glucan. To prepare the 25 kD β-glucan, macrophages are maintained in a bioreactor flask in macrophage growth serum-free medium, such as SFM medium, Invitrogen, Grand Island, NY. Labeled parent β-glucan is added to the culture. After about three weeks of cell culture, the cell-free fluid from the lower chamber of the bioreactor flask containing soluble fragments of β-glucan is collected. The β-glucan fragments are separated by, for example, high-performance liquid chromatography (HPLC) (Waters 1525, Waters Corp., Milford, MA) utilizing a monophasic gradient and separated on a Sephacryl S-200 (GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ) column. Dextran standards of known molecular weights establish an elution molecular weight profile. Fractions containing labeled material corresponding to a molecular weight of 25 kD, as detected by an appropriate detection method, are collected. The 25 kD β-glucan may be further purified and concentrated by ultracentrifugation with, for example, a Centriprep (Millipore Corp., Bedford, MA) with a 50 kD cutoff membrane.
The 25 kD β-glucan prepared by macrophage processing was evaluated against similarly sized β-glucans obtained during the manufacturing process for purifying parent β-glucan (data not shown). The sizes of these β-glucans ranged from about 10 kD to about 30 kD. Interestingly, none of the similarly sized β-glucans tested exhibited the induction activities possessed by the 25 kD β-glucan prepared by macrophage processing. It is
evident, therefore, that macrophage processing modifies the 25 kD β-glucan making a unique composition possessing characteristics that are not simply based on size.
Complement Activating Antibodies Complement activating antibodies (both naturally found or produced by methods known in the art) are antibodies directed to the tumor or tumor antigens that are able to activate one or more members of the complement cascade. In other words, an antibody that activates complement sufficiently to deposit iC3b on the tumor cells is needed. In certain embodiments, the antibodies are IgG subclass I or IgG subclass II. The present invention discloses the use of a 25 kD β-glucan with antibodies from essentially any source, including antibodies generated naturally in response to infection, antibodies generated in response to administration of a vaccine, and monoclonal antibodies directly administered as part of a therapy including the use of β- glucan. Any antibody having complement activating features can be used in the methods described herein to enhance β-glucan on tumorcidal activity. The antibody can also be a naturally occurring antibody found in the subject that is able to activate complement sufficiently to allow deposition of iC3b on the tumor cells. Murine antibodies can be raised against any antigen associated with neoplastic (tumor) cells using techniques known in the art. In this regard, tumor cells express increased numbers of various receptors for molecules that can augment their proliferation, many of which are the products of oncogenes. Thus, a number of monoclonal antibodies have been prepared which are directed against receptors for proteins such as transferring, IL- 2, and epidermal growth factor. It suffices to say that any antibody that can selectively label antigen — which is to say any antibody — could have its activity enhanced through concurrent administration with β-glucan. This includes antibodies of the various classes, such as IgA, IgD, IgE, and IgM, as well as antibody fragments such as Fab.
The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds a tumor antigen. A molecule that specifically binds to tumor is a molecule that binds to that polypeptide or a fragment
thereof, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen-binding site capable of immunoreacting with a particular epitope of a target tumor. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunorcacts. Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, e.g., polypeptide of interest or fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (e.g. , from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature, 256: 495-497, the human B cell hybridoma technique (Kozbor, et al. (1983) Immunol. Today, 4: 72), the EBV- hybridoma technique (Cole, et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R- Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally Current Protocols in Immunology (1994) Coligan, et al. (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of interest. Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating a monoclonal
antibody to a polypeptide of interest (see, e.g., Current Protocols in Immunology, supra; Galfre, et al. (1977) Nature, 266: 55052; R.H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); and Lerner (1981) Yale J. Biol. Med., 54: 387-402. Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.
Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g. , an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP™ Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs, et al. (1991) Bio/Technology, 9: 1370-1372; Hay, et al. (1992) Hum. Antibod. Hybridomas, 3: 81-85; Huse, el al. (1989) Science, 246: 1275-1281; Griffiths, el al. (1993) EMBOJ., /2: 725-734.
Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.
The present invention discloses the use of 25 kD β-glucan with antibodies from essentially any source, including antibodies generated naturally in response to infection, antibodies generated in response to administration of a vaccine, and monoclonal antibodies directly administered as part of a therapy including the use of β-glucan. The
majority of humanized mAbs containing the human IgGl Fc-region have been shown to activate complement, such as Herceptin™ (trastuzumab), Rituxan™ (rituximab), and Erbitux ™ (cetuximab) (Spiridon, C. I., et al, Clin, Cancer Res., 8: 1720-1730 (2002), Idusogie, E. E., et al, J. Immunol, 164: 4178-4184 (2000), Cragg, M. S., et al, Blood, 101: 1045-1052 (2003), Herbst, R. S. and Hong, W. K., Semin. Oncol, 29: 18-30 (2002). In certain embodiments the glucan and antibodies work synergistically.
As illustrative of the inventive concept, β-glucans could be locally administered to act synergistically with Herceptin™, a monoclonal antibody sold by Genentech for use in immunotherapy of breast cancer. Herceptin™ is a mAb that recognizes the her2 cell surface antigen which is present on 20% of breast cancer cell types. Clinical trials have demonstrated that Herceptin™ is saving lives, but its effectiveness could be significantly enhanced through concurrent administration of β-glucan. Local administration of glucan along with Herceptin™ therapy could result in a significant increase in the proportion of women responding to Herceptin™ therapy with long lasting remission of their breast cancer. Currently, only 15% of women receiving Herceptin™ therapy show long lasting remission.
Another mAb whose activity is enhanced by whole glucan particles is rituximab, a monoclonal antibody used to treat a type of non-Hodgkin's lymphoma (NHL), a cancer of the immune system. Rituxan™ (rituximab), is effective for patients with low- grade B-cell NHL who have not responded to standard treatments. It targets and destroys white blood cells (B-cells) that have been transformed, resulting in cancerous growth. Rituximab is a genetically engineered version of a mouse antibody that contains both human and mouse components. In the main clinical study of 166 patients with advanced low-grade or slow-growing NHL, which represents about 50% of the 240,000 NHL patients in the United States, tumors shrunk by at least one half in 48% of the patients who completed treatment with rituximab, with 6 % having complete remission. B-glucan can be expected to significantly increase the effectiveness of this treatment, by enhancing the destruction of antibody-marked tumor cells.
Sustained release
Long-acting formulations of the 25 kD β-glυcan can be prepared by stabilizing and encapsulating the glυcan into biodegradable microparticle formulations composed of polymers, for example polymers of lactic and glycolic acid. "Microparticles," as that term is used herein, includes a biocompatible polymer having the glucan incorporated therein. The biocompatible polymer can include, for example, poly(lactic acid) or a poly(lactic acid-co-glycolic acid) copolymer. The microparticles can be used to deliver the glucan to a patient in need thereof, for example, in a sustained manner. In certain embodiments, the microparticle is delivered locally.
Polymers used in the formulation of the microparticles described herein include any polymer which is biocompatible. Biocompatible polymers suitable for use in the present invention include biodegradable and non-biodegradable polymers and blends and copolymers thereof, as described herein. A polymer is biocompatible if the polymer and any degradation products of the polymer are non-toxic to the patient and also possess no significant deleterious or untoward effects on the patient's body, such as a significant immunological reaction at an injection or implantation site.
"Biodegradable," as defined herein, means the composition will degrade or erode in vivo to form smaller chemical species. Degradation can result, for example, by enzymatic, chemical and physical processes. Suitable biocompatible, biodegradable polymers include, for example, poly(lactides), poly(glycolides), poly(lactide-co- glycolides), poly(lactic acid)s, poly(glycolic acid)s, polycarbonates, polyesteramides, polyanydrides, poly(amino acids), polyorthoesters, poly(dioxanone)s, poly(alkylene alkylate)s, copolymers or polyethylene glycol and polyorthoester, biodegradable polyurethane, blends thereof, and copolymers thereof.
Suitable biocompatible, non-biodegradable polymers include non-biodegradable polymers such as, for example, polyacrylates, polymers of ethylene-vinyl acetates and other acyl substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinylchloride, polyvinyl flouride, poly(vinyl imidazole), chlorosulphonate polyolefins, polyethylene oxide, blends thereof, and copolymers thereof
In certain embodiments, the biocompatible polymer is at least one member selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co- glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, polycaprolactone, poly(dioxanone)s, poly(alkylene alkylate)s, polyurethanes, and blends and copolymers thereof.
Acceptable molecular weights for biocompatible polymers used in this invention can be determined by a person of ordinary skill in the art taking into consideration factors such as the desired polymer degradation rate, physical properties such as mechanical strength, and the rate of dissolution of polymer in the solvent. Typically, an acceptable range of molecular weight is of about 2,000 Daltons to about 2,000,000 Daltons. In a preferred embodiment, the polymer is a biodegradable polymer or copolymer. In another preferred embodiment, the polymer is a poly(lactide-co- glycolide) (PLG) which can have lactide:glycolide ratios of about 25:75 to about 85:15 such as about 25:75, 50:50, 75:25 and 85:15, and a molecular weight of about 5,000 Daltons to about 150,000 Daltons. In one embodiment, the molecular weight of the PLG has a molecular weight of about 5,000 Daltons to about 42,000 Daltons.
Suitable solvents, e.g., polymer solvents, suitable for production of microparticles can be determined via routine experimentation using techniques well- known to those of ordinary skill in the art. Suitable solvents include, but are not limited to, methylene chloride, acetone, acetic acid, ethyl acetate, methyl acetate, tetrahydrofuran, dimethylsulfoxide (DMSO), methyl ethyl ketone (MEK), acetonitrile, toluene, and chloroform. In one embodiment, the solvent is selected from the group consisting of methylene chloride, chloroform, ethyl acetate, methyl acetate, acetone, acetic acid, acetonitrile, dimethylsulfoxide, methyl ethyl ketone and toluene.
Methods for forming microparticles containing a glucan are described in U.S. Patent No. 5,019,400, issued to Gombotz, et al., on May 28, 1991; U.S. Patent No. 5,922,253 issued to Herbert, et al, on July 13, 1999; and U.S. Patent No. 6,455,074 issued to Tracy, et al., on September 24, 2002, the entire contents of each of which are incorporated herein by reference.
In vivo trafficking of the soluble β-glucan
The soluble β-glucan PGG (Biothera, Eagan, MN) was labeled with fluorescein dichlorotriazine (DTAF; Molecular Probes, Eugene, OR) that covalently reacts with hydroxyl groups of polysaccharides using a modification of the procedures suggested by the manufacturer. Groups of five C57BL/6 wild type mice or CR3 -deficient mice were given
1200 μg of the DTAF PGG β-glucan by tail vein injection. The spleen and bone marrow from different groups of mice were collected at day 1, day 3, and day 7. Confocal microscopy and flow cytometry were performed to determine the phenotype of fluorescence-positive cells using the following monoclonal antibodies (mAbs) CD3, CD 19, Gr-l, F4/80, NKl.l, and CDl lc.
The isolation of an active moiety of soluble β-glucans
Murine resident peritoneal macrophages were maintained in a bioreactor flask (Integra Biosciences; Chur, Switzerland) in macrophage growth serum-free medium (SFM medium, Invitrogen, Grand Island, NY). DTAF-labeled β-glucan PGG was added to the culture. Following three weeks of cell culture, the cell-free fluid from the lower chamber of the bioreactor containing soluble fragments of β-glucan PGG was collected. This material was separated by high-performance liquid chromatography (HPLC) (Waters 1525, Waters Corp., Milford, MA) utilizing a monophasic gradient and separated on a Sephacryl S-200 (GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ) column. DTAF- labeled dextran standards of known molecular weights established an elution molecular weight profile. Fractions containing DTAF-labeled material, as detected by A490 on a Waters 2996 Photodiode Array Detector, indicated a dominant bimodal peak containing material of 25 kD and a small peak containing remaining parent 150 kD β-glucan PGG. 25 kD fragments were further purified and concentrated by ultracentrifugation with a Centriprep (Millipore Corp., Bedford, MA) with a 50 kD cutoff membrane. These • fractions were confirmed to contain hexose by the phenol-sulfuric acid method.
Collection of thioglyco late-elicited peritoneal neutrophils in mice Three milliliters of BBL® fluid thioglycolate medium (Becton Dickinson,
Cockeysville, MD) were injected intraperitoneally into mice to mobilize the marginated pool
of neutrophils from the bone marrow to the peritoneal cavity. Four to six hours following thioglycolate administration, peritoneal-infiltrating neutrophils were collected using a transfer pipette by washing the cavity 4-5 times with 2-3 mL aliquots of ice-cold complete RPMI medium.
Isolation of human peripheral blood neutrophils
Utilization of human subjects was approved by the Institutional Review Board (IRB) of the University of Louisville. Following informed consent, peripheral blood was collected and neutrophils were enriched using two densities of Ficoll: 1.077 g/mL and 1.105 g/mL for separation (> 98% neutrophils).
Direct binding of 25 kD β-glucan fragments and intact β-glucan to neutrophils
Neutrophils were collected from either mice or humans as described above and resuspended in complete RPMI that had been supplemented with 10 μg/mL polymyxin B (Sigma- Aldrich, St Louis, MO) to neutralize adventitious lipopolysaccharide (LPS). Neutrophils and β-glucan were incubated at 37°C in a 5% CCh humidified incubator for 3 hours. Following the incubation, cells were washed three times. Murine neutrophils were incubated with 10 μg/mL Fc block (rat anti-mouse CD 16/32 mAb; BDPharmingen, San Diego, CA) and human neutrophils were incubated with a 1/20 dilution of heat-inactivated human serum at 0.1 mL total volume for 20 minutes at room temperature to block Fc receptors and to control false-positive staining. In some experiments, murine neutrophils were additionally stained with anti-Gr-1-PE or anti- CDl 1 β-Per CP Cy 5.5. When data were acquired by flow cytometry, the cells were gated by light scatter and propidium iodide exclusion was always utilized on a control aliquot of cells to confirm >90% cell viability.
Induction of CBRM 1/5 neo-epilope on human neutrophils
Neutrophils were collected from human donors and resuspended in complete RPMI that was supplemented with 10 μg/mL polymyxin B (Sigma- Aldrich, St Louis, MO) to neutralize LPS. As a positive control, an aliquot of neutrophils was not supplemented with polymyxin B and was instead activated with serial dilutions of LPS to induce the neo-
epitope. One million neutrophils were added to the wells of 96-well plates and mixed with either the DTAF-labeled parent β-glucan PGG or the DTAF-labeled 25 kD β-glucan active moiety that had been serially diluted in complete RPMI supplemented with polymyxin B or with LPS that had been serially diluted in complete RPMI. Neutrophils and either β-glucan or LPS were incubated at 37°C in a 5% CO2 humidified incubator for 3 hours. Following the incubation, the contents of the wells were collected and washed as described above. Inhibition of human Fc receptors was also carried out as described above. The neutrophils were then stained with an optimized dilution of CBRM 1/5 mouse anti-human CDl Ib mAb that detects the activation neo-epitope of CD lib.
In vitro CR3-dependent cellular cytotoxicity
In vitro cytotoxicity of SKOV-3 cells by β-glucan-primed human neutrophils was analyzed using a real-time measure of the impedance of electrical current by viable target cells adhered to a conductor on the bottom of wells in a 96-well plate (Acea Biosciences, Inc., San Diego, CA). Briefly, 5 X lO3 SKOV-3 cells were placed into the wells of the Acea 96-well plates and maintained in McCoys 5A medium. The SKOV-3 cells were allowed to acclimate to the environment within the plate for 24 hours. Following this incubation, fresh human serum was diluted to an equal volume of complete McCoy's medium that contained sufficient trastuzumab to make a 10 μg/mL working dilution and a final volume of 0.1 mL and added to the adherent SKOV-3 cells. The cells were incubated for 30 minutes at 37°C to permit complement activation and deposition of human iC3b. Human neutrophils, isolated from volunteers as described above, were added to achieve effector-to-target cell ratios of 10:1 and 20:1. Parent β-glucan PGG, or the 25 kD fragments derived from co- culture of macrophages and β-glucan PGG, was added to the neutrophils to prime CR3. The primed neutrophils were added in a final volume of 0.1 mL to the iC3b-opsonized tumor cells. Control wells contained iC3b-opsonized tumors and non-β-glucan-primed neutrophils to measure the contribution of ADCC to the cytotoxicity. Cells were incubated at 37°C in a humidified 5% CO2 incubator for 12 hours. The CR3-DCC cytotoxicity of target cells was calculated by measuring the ratio of the cell indices, or the relative decrease in current impedance, among wells containing iC3b-opsonized SKOV-3 cells and β-glucan-
primed neutrophils and wells containing iC3b-opsonized SKO V-3 cells and non-β-glucan- primed neutrophils. For some experiments, Syk kinase inhibitor Piceatannal (Sigma- Aldrich, St. Louis, MO) or PI 3-kinase inhibitor LY294002 (Calbiochem, Darmstadt, Germany) was added to the cytotoxicity assay.
Dual ligation o/CR3 and measurement of Syk phosphorylation and PI 3-kinase activity
Human neutrophils were stimulated with anti-Ml/70 mAb (1 μg/ml) followed with goat-anti-rat Ig (5 μg/ml) in the presence or absence of the 25 kD active moiety of β-glucan (10 μg/ml) at 37°C. To detect Syk phosphorylation, cells were stimulated for 30 minutes and lysed by lysis buffer. The supematants were incubated with a cocktail of anti-CR3 mAbs (OKM-I, MN-41, MO-I5 LM-2) and 40 μl of Protein A-agarose for two hours at 4°C. The agarose beads were pelleted, washed three times with lysis buffer, suspended in SDS sample buffer and boiled for five minutes. The immunoprecipitates were analyzed on SDS-PAGE gel. Proteins were transferred onto nitrocellulose membranes and blotted with anti-phospho-Syk antibody or anti-Syk antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The bound antibody was detected using enhanced chemiluminescence (Cell Signaling Technology, Beverly, MA). For measurement of PI 3-kinase activity, cells were stimulated for one hour and aliquots of cell lysates adjusted for protein concentration (500 μg of protein) were incubated for two hours at 4°C with anti-PI 3-kinase p85 antibody, and immune complexes were adsorbed onto protein A-agarose for three hours. The complexes were then washed twice with lysis buffer and three times with 10 mM Tris-HCl, pH 7.4. To ensure that PI 3-kinase levels remained equivalent at the end of the immunoprecipitation, 10% from each treatment sample were collected during the last wash in a separate tube and analyzed by SDS-PAGE and immunoblotting with Abs to the p85 PI 3-kinase subunit PI-3K activity was assayed with PI-3K ELISA kit (Echelon Biosciences, Salt Lake City, UT) according to manufacturer's instructions (An, H., et al, Src homology 2 domain-containing inositol-5- phosphatase 1 (SHIPl) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism, Blood 105, 4685-92 (2005)). In brief, cell lysates were prepared and PI-3K was immunoprecipitated with antibody against the p85 subunit and incubated with PI(4,5)P2 (phosphatidylinositol-4,5- diphosphate). The reaction products were incubated with a PI(3,4,5)P3 detector protein then
added to a PI(3,4,5)P3-coated microplate for competitive binding. A peroxidase-linked secondary detection reagent and colorimetric detection were used to detect PI(3,4,5)P3 detector protein binding to the plate. The colorimetric signal was inversely proportional to the amount of PI(3,4,5)P3 produced by PI-3K activity.
In vivo tumor therapy
RMA-S-MUCl is a C57BL/6 T cell lymphoma that does not express MHC class I as a consequence of a mutation in the gene encoding the transporter associated with Ag presentation (TAP) protein, and was kindly provided by Dr. Olivera J. Finn (University of Pittsburgh). Briefly, 1 x 106 RMA-S-MUCl cells were implanted subcutaneously in a mammary fat pad of wild-type C57BL/6 or CR3-deficient mice (n=l 0). After seven days, when tumors of 1-2 mm appeared, the mice were divided into groups of ten and therapy was initiated with 14 G2a antiGD2 mAb or BCP8 anti-MUCl mAb (200 μg intravenously (i.v.) twice weekly) with or without i.v. β-glucan PGG (1200 μg/mouse, twice a week). Therapy was continued for three weeks during which time tumor measurements by calipers were calculated as the average of perpendicular diameters twice weekly. Mice were sacrificed when tumors reached 12 mm in diameter. Survival was monitored for a period of 100 days beyond the tumor implantation.
Statistical analysis
Data were entered into Prism 4.0 (Graph Pad Software, San Diego, CA) to generate graphs of percentage of fluorescent positive cells or tumor regression, and Student's 7' test was employed to determine the significance of differences between two data sets. Survival curves were created using the Kaplan-Meier method and statistical analyses of survival curves util ized a log-rank test.
The above materials and methods were used in the experiments below:
Experiment 1 C57B1/6 mice or CR3-deficient mice (n=10) were implanted subcutaneously with
RMA-S-MUCl cells, and a tumor was allowed to form over seven days before initiating
immunotherapy. Mice were treated with BCP-8 anti-MUCl mAb (200 μg twice a week) and/or β-glucan PGG (1200 μg twice a week) for a total of three weeks. Tumor growth (FIG. Ia) and survival (FIG. Ib) were monitored. Mean values ± SE of the mean are shown.
Results:
Intravenous administration of β-glucan PGG twice a week to tumor-bearing mice, in combination with an anti-tumor mAb, almost completely suppressed tumor growth and greatly increased survival, whereas administration of mAb alone had no effect (FIG. la,b). In contrast, tumor-bearing mice treated with nothing (PBS) (not shown), β-glucan alone (not shown) or mAb alone had similar unrestrained tumor growth (FIG. Ia). This tumor suppressive effect of β-glucan with mAb was not seen in CR3-deficient (CR37") mice, suggesting that soluble β-glucan mediated tumor therapy is CR3 dependent
Experiment 2
Mice were given fluorescein DATF-labeled PGG β-glucan intravenously and were sacrificed at day 1, day 3, and day 7. The spleens were frozen-sectioned and slides were stained with F4/80-PE or anti-Gr-1-PE. Original magnification was 6OX (FIG. 2a,b). Cells from the spleen or bone marrow (BM) were stained with F4/80, anti-Gr-1 mAbs and analyzed by flow cytometry. The cells with surface bound fluorescent β-glucan were gated on F4/80+ or Gr-I+ cells (n=5). Thioglycolate elicited macrophages or neutrophils from wildtype (WT) or CR3-deficient (CR3V~) mice were incubated with DTAF-labeled PGG β~ glucan. Cells were observed under confocal microscopy and also analyzed by flow cytometry, respectively. Original magnification was IOOX (FIG. 2c). Peritoneal neutrophils from WT and CR3V" mice receiving DTAF-labeled β-glucan PGG were marginated by thioglycolate injection at day 7 and stained with anti-Gr-1-PE. Original magnification was IOOX (FIG. 2d). Neutrophils from above were then stained with anti-Gr-1 mAb and analyzed by flow cytometry. The cells with surface bound fluorescent β-glucan were gated on Gr-I+ cells (n=5) (FIG. 2e). The neutrophils from above were also assayed for cytotoxicity using iC3b-opsonized RMA-S-MUCl tumor cells as targets as described in the methods (FIG. 2f).
Results:
One day following administration of fluorescein-labeled β-glucan to mice, the polysaccharide appeared in splenic MΦ, but not in neutrophils (FIG. 2a). However, seven days following injection, β-glucan positive macrophages virtually disappeared from the spleen while approximately 10% of neutrophils, in both the spleen and bone marrow, were now found to contain β-glucan (FIG. 2a,b).
Thioglycolate-elicited peritoneal MΦ and neutrophils from wildtype (WT) and CR3"Λ mice were harvested and incubated with fluorescein-labeled β-glucan to determine the possible importance of CR3. Macrophages from WT and CR3'1' mice had comparable uptake of β-glucan as assessed by both fluorescence microscopy and FACS analysis, suggesting that the uptake of intact β-glucan by MΦ is CR3-independent (FIG. 2c). The uptake of labeled β-glucan was blocked by a 10-fold excess of unlabeled β-glucan (data not shown). Interestingly, the labeled β-glucan did not bind to the neutrophils in these preparations, suggesting that the β-glucan that bound to neutrophils in vivo seven days following administration (FIG. 2a) might be a modified form of the parent β-glucan, perhaps arising from processing of the original material by MΦ and subsequent release of the β-glucan fragments to neutrophils. Peritoneal neutrophils, elicited by thioglycolate, were then examined from WT and CR3V~ mice seven days after administration of labeled β- glucan to further explore the importance of CR3 in the priming of neutrophils per se. Granulocytes from WT mice that had not been given β-glucan served as a control for the ability of non-glucan-exposed neutrophils to kill iC3b-coated tumor cells. Neutrophils from WT mice, but not CR3~'~ mice exhibited β-glucan binding by both fluorescence microscopy (FIG. 2d) and FACS analysis (FIG. 2e). Furthermore, these WT neutrophils with surface- bound β-glucan were capable of killing iC3b-opsonized RMA-S-MUCl tumor cells. The requirement for CR3 was confirmed by abolished tumor killing mediated by neutrophils from CR3V' mice (FIG. 2f). Therefore, uptake of parent β-glucan by MΦ does not require CR3. However, degradation fragments, presumably the active fragments, released from MΦ are bound by WT but not CR3V" neutrophils, and the former are capable of killing iC3b-opsonized tumor cells.
Experiment 3
Peritoneal neutrophils from WT and CR3V" mice were stained with DTAF-labeled β-glucan PGG (FIG. 3a-upper panel) or with DTAF-labeled 25 kD active moiety released from macrophage culture (FIG. 3a-lower panel). Human CR3 transfected CHO cells were cultured in glass-plates and stained with anti-CR3-PE and DTAF-labeled parent β-glucan PGG or 25 kD β-glucan (FIG. 3b). Slides were observed under Nikon fluorescent microscope. Original magnification was 2OX. Peritoneal neutrophils from WT and CR3V" mice or human peripheral blood neutrophils were stained with various amounts of DTAF- labeled parent β-glucan PGG or 25 kD β-glucan. The cells with surface bound fluorescent β-glucan were gated on Gr-I+ cells (FIG. 3c,d). Human peripheral blood neutrophils were incubated with varying concentrations of parent β-glucan PGG or 25 kD β-glucan and stained with anti-CBRMl/5 mAb (FIG. 3e). Human neutrophils were co-cultured with iC3b-opsonized SKO V-3 tumor cells in the presence of varying concentrations of parent β- glucan PGG or 25 kD β-glucan for cytotoxicity assay as described in the methods (FIG. 3f). The E:T ratio was 20: 1.
Results:
In an attempt to identify the nature of this putative active fragment, an in vitro MΦ culture system was used in which resident peritoneal MΦ were exposed to fluoroscein- labeled intact β-glucan. Long-term incubation resulted in the appearance of a β-glucan fragment with an approximate molecular size of 25 kD by high-resolution high-performance liquid chromatography. This fragment, but not the parent β-glucan, bound directly to mouse and human neutrophils or CR3 transfected CHO cells (FIG. 3a,b). The binding of this 25 kD β-glucan fragment by mouse neutrophils was CR3-dependent (FlG. 3c) and saturable (FIG. 3d). Thus, it appears that the 25 kD β-glucan fragment, but not the 150 kD parent molecule, mediates CR3-dependent binding to neutrophils and subsequent biological functions.
Human neutrophils were exposed to this fragment to further characterize the bioactivity of the 25 kD β-glucan and the appearance of the "activated" epitope of CDllb/CD18 (CR3), detected with the mAb CBRM 1/5, was assessed. Neutrophils
stimυlated by the 25 kD β-glucan fragment, but not parent β-glucan, induced CBRM 1/5 expression in a dose-dependent manner (FIG. 3e). In these experiments, exogenous LPS contamination was controlled by maintaining all buffers with 10 μg/ml polymyxin B. These data indicate that the 25 kD β-glucan fragment could effect the CR3-dependent priming of neutrophils and might promote neutrophil killing of iC3b-opsonized targets. Indeed, the 25 kD β-glucan, but not parent β-glucan, greatly amplified the cytotoxicity of neutrophils against iC3β-opsσnized human ovarian carcinoma cells in a dose-dependent fashion (FIG. 3f). Therefore, the 25 kD β-glucan, not the parent β-glucan, is necessary and sufficient for CR3-dependent, neutrophil-mediated cytotoxicity against iC3b-opsonized tumor cells.
Experiment 4
Human peripheral blood neutrophils were stimulated with rat anti-human/mouse CR3 I-domain mAb M 1/70 followed by goat anti-rat secondary antibody (with or without 25 kD β-glucan) or 25 kD β-glucan alone for 30 minutes. Cell lysates were immunoprecipitated with a cocktail of anti-CR3 mAbs and the immunoprecipitates were analyzed on SDS- PAGE gel. Proteins were transferred onto nitrocellulose membranes and blotted with anti- Syk antibody or anti-phospho-Syk antibody, respectively (FIG. 4a).
Human peripheral blood neutrophils were also stimulated with 25 kD β-glucan, M 1/70 mAb followed by secondary Ab, or both for 30 minutes. Cells were fixed, permeabilized and stained with antiphospho-Syk mAb or isotype control antibody. Cells were assessed by flow cytometry. Mean fluorescence intensity was compared in each stimulation condition (FIG. 4b).
Additionally, human peripheral blood neutrophils were stimulated with Ml/70 mAb followed by secondary Ab (with or without 25 kD β-glucan) or 25 kD β-glucan alone for one hour. Cell lysates were immunoprecipitated with anti-PI 3-kinase p85 mAb. The immuprecipitates were analyzed on SDS-PAGE gel and blotted with anti-PI 3-kinase p85 mAb. The immunprecipitates were also measured for PI 3-kinase activity by ELISA. The PI 3-kinase activity was represented as the level of PI(3,4,5)P3 (PI3P3) (FIG. 4c).
Human peripheral blood neutrophils were also stimulated with M 1/70 mAb followed by secondary Ab with 25 kD β-glucan in the presence or absence of PI 3-kinase
inhibitor LY294002 (50 μM) and/or Syk kinase inhibitor Piceatannol (25 μM) for one hour. Cells were imtnunoprecipated with anti-PI 3-kinase p85 mAb and PI 3-kinase activity was measured by ELISA. The PI 3-kinase activity was arbitrarily setup as 100% for neutrophils stimulated with dual ligation (31.45±3.8 pM). The percentage of PI 3-kinase activity was generated by PI 3-kinase activity from inhibitor treated cells divided by that from dual ligation stimulated cells (9.05±1.14 />M for LY294002 and 17.1±1.5 pM. for Piceatannol, respectively) (FIG. 4d).
In addition, human neutrophils were co-cultured with iC3b-opsonized SKOV-3 tumor cells and 25 kD β-glucan in the presence or absence of PI 3-kinase inhibitor LY294002 (50 μM) and/or Syk kinase inhibitor Piceatannol (25 μM). The E:T ratio was 20:1. The cytotoxicity was arbitrarily set up as 100% for neutrophils stimulated with 25 kD β-glucan (35.7%±3.61%). The percentage of CR3-dependent cellular cytotoxicity was generated by cytotoxicity from the inhibitor treated group divided by that from the non-treated group (7.88%±1.39% for LY294002 and 16.15%±2.68% for Piceatannol, respectively) (FIG. 4e).
Results:
Syk phosphorylation was enhanced by dual ligation of CR3 and co-precipitated with CR3. This was confirmed by western blot (FIG. 4a) and intracellular anti-phospho-Syk Ab staining assessed by flow cytometry (FIG. 4b). The results indicate that CR3- dependent cytotoxicity against iC3b-opsonized yeast or tumor cells requires simultaneous ligation of two distinct binding sites in CR3: one for iC3b and the second for β-glucan (Vetvicka, V., Thornton, B.P. & Ross, G.D., "Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CDllb/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells," J. Clin. Invest. 98, 50-61 (1996); Vetvicka, V., Thornton, B.P., Wieman, T.J. & Ross, G.D., 'Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucanprimed CR3 (CD lib/CD 18)," J. Immunol. 159, 599-605 (1997)). However, it remains unknown how this dual ligation acts to prompt neutrophil cytotoxicity. Prior investigations of integrin signaling in phagocytes demonstrated a hierarchical activation of the Src-family kinase and Syk
(Berton, G., et al, Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 26, 208-14 (2005)). Syk activation in particular may be crucially important because immobilized anti-CDl lb induces a respiratory burst in WT but not Syk- deficient neutrophils (Mocsai, A., et al., Syk is required for integrin signaling in neutrophils, Immunity 16, 547-58 (2002)).
Following CR3 dual ligation, increased PI 3 -kinase activity compared to Ab or glucan stimulation only was observed (FIG. 4c). In further support of the activation of PI 3-kinase by phospho-Syk, it was observed that the Syk kinase inhibitor, Piceatannal (25 μM), significantly blocked this increase in PI 3-kinase activity (FIG. 4d). This particular mechanism of signaling appears to be crucial because both the PI 3-kinase inhibitor, LY294002 (50 μM), and the Syk kinase inhibitor, Piceatannal (25 μM), potently blocked dual ligation-mediated cytotoxicity (FIG. 4e). Abrogation of cytotoxicity was proportional to the inhibition of PI 3-kinase activity mediated by either inhibitor (FIG. 4d,e) and a higher dose of the PI 3-kinase inhibitor, LY294002 (100 μM), completely abrogated β- glucan mediated cytotoxicity (data not shown).
The work presented here provides a more complete picture of the mechanisms involved in the anti-tumor effects of β-glucan in combination with anti-tumor mAbs. Intact β-glucan is first taken up by MΦ and cleaved into a 25 kD active fragment. This active fragment binds to neutrophil CR3 and primes these cells for target killing through signaling events involving both Syk and PI 3-kinase. These data provide a rationale for combining yeast β-glucan with complement activating anti -tumor mAbs such as Rituxan®, (rituximab, Biogen Idee, MA) and Herceptin®, (trastuzumab, Genetech, Inc., CA) to promote CR3-dependent attack on tumors.
The accompanying research article entitled 'Υeast β-Glucan Amplifies Phagocyte Killing of iC3b-opsonized Tumor Cells via CR3-Syk-PI3-kinase Pathway" by Li et al. is hereby incorporated by reference.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims
1. A local delivery composition comprising a 25 kD β-glucan with 1,3 linked glucose with 1,6 glucose branches with 1,3 linked glucose side chains for local administration to a tumor site.
2. The composition of Claim 1, further comprising a monoclonal antibody.
3. The composition of Claim 1, wherein the composition is a sustained release composition.
4. A method of treating tumors comprising locally administering to the tumor the composition of Claim 1 and a monoclonal antibody.
5. A method of enhancing the CR3 -dependent neutrophil-mediated cytotoxicity against iC3β-oponized tumor cells, comprising locally administering a 25 kD size β-glucan to the tumor site and a monoclonal antibody, wherein the CR3-dependent neutrophil-mediated cytotoxicity against iC3b-opsonized tumor cells is enhanced.
6. The method of Claim 4, wherein intracellular signaling via Syk phosphorylation is enhanced.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07796158A EP2032591A2 (en) | 2006-06-15 | 2007-06-15 | Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81414806P | 2006-06-15 | 2006-06-15 | |
US60/814,148 | 2006-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007146417A2 true WO2007146417A2 (en) | 2007-12-21 |
WO2007146417A3 WO2007146417A3 (en) | 2008-05-15 |
Family
ID=38832561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014056 WO2007146417A2 (en) | 2006-06-15 | 2007-06-15 | Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity |
Country Status (3)
Country | Link |
---|---|
US (1) | US20090047288A1 (en) |
EP (1) | EP2032591A2 (en) |
WO (1) | WO2007146417A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2155000A1 (en) * | 2007-05-08 | 2010-02-24 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Particulate-soluble glucan preparation |
EP2231712A1 (en) * | 2007-12-19 | 2010-09-29 | Valtion Teknillinen Tutkimuskeskus | Method of processing beta-glucan |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007146416A2 (en) | 2006-06-15 | 2007-12-21 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Glucan preparations |
US9694128B1 (en) * | 2010-02-24 | 2017-07-04 | Brian LeBerthon | Device and method for administering an anti-cancer substance |
US9227005B2 (en) | 2013-03-14 | 2016-01-05 | Brian J LeBerthon | Method and device for treating cancer |
EP3166616B1 (en) | 2014-07-10 | 2021-04-07 | Biothera, Inc. | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment |
CN107106593B (en) | 2014-11-06 | 2021-05-07 | 百奥赛诺公司 | Beta-glucan methods and compositions for affecting tumor microenvironment |
US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130127A (en) * | 1985-03-11 | 1992-07-14 | The Wistar Institute | Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies |
US5811542A (en) * | 1989-09-08 | 1998-09-22 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070778B2 (en) * | 2003-10-30 | 2006-07-04 | Laboratoire Goemar Sa | Therapeutical combination against cancer |
-
2007
- 2007-06-15 EP EP07796158A patent/EP2032591A2/en not_active Withdrawn
- 2007-06-15 WO PCT/US2007/014056 patent/WO2007146417A2/en active Application Filing
- 2007-06-15 US US11/818,697 patent/US20090047288A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130127A (en) * | 1985-03-11 | 1992-07-14 | The Wistar Institute | Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies |
US5811542A (en) * | 1989-09-08 | 1998-09-22 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
Non-Patent Citations (1)
Title |
---|
MODAK S. ET AL.: 'Rituximab therapy of lymphoma is enhanced by orally administered (1 3,(1 4)-D-beta-glucan' LEUKEMIA RESEARCH vol. 29, 2005, pages 679 - 683, XP004867120 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2155000A1 (en) * | 2007-05-08 | 2010-02-24 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Particulate-soluble glucan preparation |
EP2155000A4 (en) * | 2007-05-08 | 2013-12-25 | Biothera Inc | Particulate-soluble glucan preparation |
EP2231712A1 (en) * | 2007-12-19 | 2010-09-29 | Valtion Teknillinen Tutkimuskeskus | Method of processing beta-glucan |
EP2231712A4 (en) * | 2007-12-19 | 2013-12-25 | Valtion Teknillinen | Method of processing beta-glucan |
Also Published As
Publication number | Publication date |
---|---|
WO2007146417A3 (en) | 2008-05-15 |
US20090047288A1 (en) | 2009-02-19 |
EP2032591A2 (en) | 2009-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9522187B2 (en) | Cancer therapy using beta glucan and antibodies | |
US20090047288A1 (en) | Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity | |
Hong et al. | Mechanism by which orally administered β-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models | |
US20100166751A1 (en) | Cancer therapy using whole glucan particles and antibodies | |
JP7360418B2 (en) | Beta-glucan methods and compositions that influence the intratumoral microenvironment | |
US20080063650A1 (en) | mCRP antagonists and their uses | |
JP2019506412A (en) | Novel anti-LAM and anti-PIM6 / LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infection | |
JP6893594B2 (en) | Β-Glucan in combination with antineoplastic agents that affect the tumor microenvironment | |
CN109195992A (en) | Polyspecific combination conjugate, relevant pharmaceutical composition and application | |
JP2019525934A (en) | Combination therapy with melestinib and anti-PD-L1 or anti-PD-1 inhibitor for use in the treatment of cancer | |
Korycka-Wołowiec et al. | Ofatumumab for treating chronic lymphocytic leukemia: a safety profile | |
EP3233104B1 (en) | Immunotherapy treatments and compositions | |
EP2461870B1 (en) | Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors | |
EP4082577A1 (en) | Cancer treatment method and medicine | |
Liu et al. | Yeast-derived β-glucan in combination with anti-tumor monoclonal antibody therapy in cancer | |
Yan et al. | β-Glucan-mediated tumor immunotherapy-mechanisms of action and perspective | |
Wang et al. | Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and-9 | |
Allendorf | Cellular and molecular mechanisms of action of beta-glucans for tumor immunotherapy in syngeneic and translational animal models | |
Hong | Determination of the potential use of β-glucan as an adjuvant for monoclonal antibody immunotherapy of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07796158 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007796158 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |